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MAST CELLS MEDIATE SYSTEMIC IMMUNOSUPPRESSION INDUCED BY 
PLATELET-ACTIVATING FACTOR VIA HISTAMINE AND  
CYCLOOXYGENASE-2 DEPENDENT MECHANISMS 
 
 Platelet-activating Factor (PAF) stimulates various cell types by the activation of 
the G-protein coupled PAF-receptor (PAFR). Systemic PAFR activation induces an acute 
pro-inflammatory response, as well as delayed systemic immunosuppressive effects in 
vivo. De novo enzymatic PAF synthesis and degradation are closely regulated, but 
oxidative stressors, such as UVB, and cigarette smoke, can generate PAF-like species via 
the oxidation of membrane lipids in an unregulated process. Mast cells (MCs) and the 
PAFR have been shown to be necessary to mediate the resulting systemic immune 
suppression from oxidative stressors. The work herein implicates pro-oxidative 
chemotherapeutics, such as melphalan and etoposide, in mediating augmentation in tumor 
growth by inducing the generation of PAFR agonists via the oxidation of membrane 
lipids. This work also demonstrates the role of MCs and MC-released mediators in PAFR 
systemic immunosuppression. Through a contact hypersensitivity (CHS) model, the MC 
PAFR was found to be necessary and sufficient for PAF to mediate systemic 
immunosuppression. Additionally, activation of the MC PAFR seems to induce MC 
histamine and prostaglandin E2 release. Furthermore, by transplanting histamine- or 
COX-2-deficient MCs into MC-deficient mice, MC-derived histamine and prostaglandin 
release were found to be necessary for PAF to induce systemic immunosuppression. 
  vi 
Lastly, we have evidence to suggest that prostaglandin release modulates MC migration 
to draining lymph nodes, a process necessary to promote immunosuppression. These 
studies fit with the hypothesis that MC PAFR activation mediates PAFR systemic 
immunosuppression in part by histamine and prostaglandin release. 
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Chapter 1: Introduction and Literature Review 
I. PAF 
 As a result of tissue damage, infection, or exposure to immunogenic molecules, 
the body coordinates inflammatory responses by orchestrating various cell types through 
the release of soluble mediators [1]. These soluble mediators drive the balance between 
pro-inflammatory and anti-inflammatory mechanisms. Platelet-activating factor (PAF) is 
a soluble lipid mediator of both local acute inflammation as well as delayed systemic 
immunosuppression [2-8]. Still, the mechanism of PAFR-mediated immunosuppression 
remains to be fully elucidated.  
A. PAF physiology 
 PAF (1-hexadecyl-2-acetyl-glycerophosphocholine, Figure 1) is among the most 
potent phospholipids known, inducing asthma-like responses in the low picomolar range 
[9], and resulting in anaphylaxis at higher doses [10]. PAF was first described when 
Henson proposed in 1971 that there was a leukocyte-derived soluble mediator that 
activated platelets [11]. It was not until 1972, however, when PAF was first identified as 
the mediator released by stimulated basophils that resulted in platelet aggregation [12]. 
This activity is due to multiple glycerophosphocholines (GPCs), with 1-hexadecyl-2-
acetyl GPC being the most potent.  Expression of its G-protein coupled receptor (GPCR), 
PAFR (Ptafr), has been demonstrated in many tissues and cell types, including: platelets, 
neutrophils, macrophages, dendritic cells, langerhans cells, keratinocytes, mast cells, 
neurons, myometrium, vascular endothelial cells and tracheal epithelial cells [13, 14]; and 
also many tissues such as: brain, kidney, skeletal muscle, smooth muscle, and alveoli in 
the lung [13].  
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Figure 1. Structure of GPC, PAF and CPAF. 
A. General structure of GPC. Glycerol position C1 (sn-1) consists of hexadecyl ether 
group, C2 (sn-2) is an acetyl linkage (typically arachidonate), C3 (sn-3) is a 
phosphocholine group. B. The structure of PAF. C. The structure of N-methylcarbamyl 
PAF. 
A 
B 
C 
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 PAF stimulates the activation of platelets, and leukocytes in response to 
traumatic, allergic, and infectious events [15-17]. In particular, PAF has been shown to 
promote platelet aggregation, induce smooth muscle contraction, initiate 
bronchoconstriction and tracheal mucus secretion, promote vasoconstriction, 
vasodilatation and vascular leakiness, promote neuron maturation and synapse formation 
at physiologic concentrations, and induce neuronal, astrocyte, and oligodendrocyte 
apoptosis at supraphysiologic concentrations [4-6, 10, 15]. Relevant to the immune 
system, PAF is known to induce macrophage, neutrophil and eosinophil 
chemoattraction,[18-20] and neutrophil extracellular trap release [21]. B lymphocyte cell 
lines also express functional PAFRs [22].  While, the expression of PAFR on T 
lymphocytes remains controversial [5], we have evidence to support the absence of 
PAFR expression in T cells.  
 PAF is released after mast cell, endothelial cell, platelet, neutrophil, basophil, and 
macrophage activation, as well as following reperfusion injury and ischemia [4-6, 10, 15, 
23]. PAF is synthesized under tightly regulated enzymatic pathways (Figure 2), as well as 
unregulated mechanisms mediated by oxidative stressors (Figure 3). Under physiological 
conditions, phospholipase A2 cleaves the fatty acid moiety on the second carbon in the 
glycerophosphocoline glycerol backbone to generate a lyso intermediate, which 
undergoes acetylation by PAF synthases to generate enzymatically synthesized PAF. 
Alternatively, PAFR agonists readily form non-enzymatically via the free-radical 
oxidation of GPCs to render oxidized-GPCs (ox-GPCs). This process is mediated by 
reactive oxygen species (ROS) generated by pro-oxidative stressors, such as ultraviolet 
light B (UVB) and cigarette smoke [24, 25].  
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Figure 2. The enzymatic synthesis of PAF.  
GPCs from lipid membranes are cleaved at the glycerol C2 (sn-2) position by PLA2, 
liberating arachidonic acid and Lyso-PAF. Free arachidonic acid is then converted to 
leukotrienes by 5-lipooxygenase, or thromboxanes and prostaglandins by COX-1 or 
COX-2. Lyso-PAF is acetylated by LPCAT to form PAF. This acetylation reaction is 
reversible by the cleavage of the C2 acetyl group by PAF-AH forming lyso-PAF which 
is then re-acylated to form GPC or re-acetylated to form PAF.  
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Figure 3. Proposed outcomes of PAFR-agonistic ox-GPC formation. 
Basal state triplet oxygen (3O2) is activated to singlet oxygen (1O2) or superoxide 
radical (O2•-) by pro-oxidative stressors. Superoxide radical can then be resolved to 
other ROS including hydrogen peroxide and hydroxide radical. These ROS oxidize 
unsaturated bonds in GPCs, predominantly arachidonate in the C2 glycerol position 
due to rich π-electron bonding systems. These intermediates can resolve in many ways 
including butenoyl-PAF and a stabilized radical (above), or by metal (M++) catalysis 
resolve to give PAF, butanoyl-PAF, among many other possible mechanisms.  
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B. Structure and synthesis of PAF 
 PAF (Figure 1) is derived from GPCs, the major component of lipid membranes 
in cells and organelles. PAF is made up of a phosphocholine group on the sn-3 position 
of a glycerol backbone, while an ether-linked alkyl and an acetyl group fill sn-1 and sn-2 
positions, respectively. Under physiological conditions, phospholipase A2 (PLA2), under 
the control of Ca2+, ERK and p38, cleaves the fatty acid moiety on the sn-2 position of 
the GPC glycerol backbone to generate a lyso intermediate. This intermediate undergoes 
acetylation by PAF synthases, such as lysophosphatidylcholine acyltransferase to 
generate enzymatically synthesized PAF. Alternatively, PAFR agonists readily form non-
enzymatically via the free-radical oxidation of GPCs, a process mediated by ROS 
generated by oxidative stressors, such as UVB and cigarette smoke. The mechanism of 
this reaction has been explored in some detail [24-26]. Generally, ROS react with and 
oxidize unsaturated groups in the fatty acid chain on the sn-2 position of GPCs. The 
products that result from the resolution of this unstable intermediate can result in the 
cleavage of the sn-2 fatty acid and a variety of PAF-like ox-GPCs (Figure 2). This 
reaction is favorable because fatty acids in this position, typically arachidonic acid, have 
π-electron rich bonding systems that are highly reactive with ROS. Once synthesized, 
however, PAF agonists can be broken down into their lyso intermediate by circulating 
PAF-acetyl hydrolases (PAF-AH, also known as lipoprotein-PLA2), or by intracellular 
PAF-AH II via the hydrolysis of the sn-2 ester bond [27]. Experimentally, it has been 
shown that the half-life of circulating PAF is less than 7 minutes in humans and 30 
seconds in mice [28]. For this reason, N-methylcarbamyl-PAF (CPAF), a metabolically 
stable PAFR agonist, is used in research.  
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C. Structure and pharmacology of the PAFR 
 The effects of PAF in anaphylaxis and asthma have long been recognized, while 
the identification of the PAFR remained elusive until it was first cloned in 1991 [29]. The 
PAFR is highly specific to PAF and binds PAF with a KD (binding affinity) of 0.61 nM 
[30]. ED50 values have been demonstrated to range in the low nM range [8]. Hydropathy 
analysis demonstrated the presence of seven hydrophobic transmembrane domains in the 
protein sequence of PAFR, consistent with the structure of a GPCR [29]. This evidence 
was consistent with observations that the effects of PAF are mediated by G-proteins [3]. 
The PAFR gene is regulated by two sets of promoters on the 5’ non-coding region of the 
gene [5]. This gives rise to two different PAFR transcripts that are differentially regulated 
and are hypothesized to have different signaling pathways.  
 Early work on this field found that heterotrimeric G-proteins bind a ligand-bound 
PAFR resulting in the release of stored calcium, decrease in cyclic AMP, an increase in 
inositol triphosphate and release of arachidonic acid (Figure 4) [3]. Studies have shown 
that Gαi classically mediates a decrease in cAMP by inhibition of adenylate cyclase, 
following PAFR activation. Furthermore, it has been shown that PAFR mediates 
activation of: Erk by Gαq/11, Gαo and Gβγ, PLCβ by Gαq/11 and Gαo, and p38 by 
Gαq/11. Interestingly, PAF has been shown to mediate some effects via non-G-protein 
dependent pathways. In particular, Jak/STAT pathway activation has been demonstrated 
to be the result of Tyk activation by PAFR (Figure 4). These intracellular signaling 
pathways have been implicated in various cell-specific effects ranging from chemotaxis 
to survival and proliferation.   
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Figure 4. Intracellular signaling following PAFR activation.  
Activation of PAFR stimulates G-protein and non-G-protein mechanisms. PAFR can 
activate Tyk2/STAT pathways via independent of G-proteins. Alternatively, PAFR can 
activate (green arrows) or repress (red arrows) secondary messengers via G-protein 
activation. PAFR activation can repress adenylyl cyclase (AC) via Gαi, and activate 
phospholipase C (PLC) via Gαq/11 and Gαo. Activation of PLC results in cleavage of 
PIP2 to render free DAG and IP3, which activate PKC by sequestering PKC to the cell 
membrane and inducing intracellular calcium release, respectively. Additionally, PAFR 
can activate p38 and Erk MAP kinase pathways via G-protein dependent mechanisms.  
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 Additionally, several lines of evidence have implicated the role of epidermal growth 
factor receptor (EGFR) in mediating cell proliferation (Figure 5) [31-33]. 
 Cloning the PAFR made the generation of PAFR overexpressing and PAFR 
deficient (KO) mice possible, which was accomplished by Satoshi Ishii in 1997 and 
1998, respectively [34, 35]. The PAFR overexpressing mouse was generated by inserting 
a transgenic copy of the PAFR cDNA under the control of a CMV enhancer and β-actin 
promoter. Interestingly, these mice were found to demonstrate increased endotoxin 
sensitivity, increased bronchial reactivity, and greater spontaneous melanocytic 
tumorigenesis [34]. The PAFR KO mouse was generated by disrupting the PAFR gene 
with a PGK-neo cassette insertion into the open-reading frame. This mouse was shown to 
develop and reproduce normally, and maintains sensitivity to endotoxin, but has 
decreased sensitivity to anaphylaxis by intravenous OVA administration in OVA-
sensitized mice [35]. Other studies have shown that this mouse may be predisposed to 
obesity with age and may be protected from oophorectomy–related osteoporosis. More 
recently, however, this mouse has been shown to be resistant to UVB-induced systemic 
immunosuppression [36].  
D. PAF: pro-inflammatory and anti-inflammatory homeostasis 
 One of the essential characteristics of all living organisms is the need to maintain 
homeostasis. For complex organisms, this includes mounting robust immune responses to 
fight off infection or repair tissues, but also having the ability to attenuate this response 
when the injury or infection resolves. The inability to mount an appropriate immune 
response can leave the organism vulnerable to lethal disseminated infection. This is 
highlighted in patients with severe immunodeficiency disorders.   
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Figure 5. Extracellular signaling following PAFR activation.  
Activation of PAFR stimulates signal transduction via EGFR-mediated mechanisms. 
PAFR can activate (green arrows) PLC and AC pathways through Gαq activation. 
PLC activation leads to Ca2+ release which activates Src mediated activation of a 
disintegrin and metalloproteinase (ADAM). Activation of AC increases cAMP 
concentrations that activate PKA, which can induce the upregulation of 
metalloproteases (MMPs) via the phosphorylation of transcription factor cAMP 
response element-binding protein (CREB). Released MMPs and activated ADAMs can 
cleave (orange arrows) surface bound epidermal growth factor (EGF), which activate 
membrane-bound EGFR. EGFR induces cell proliferation and cell survival via the 
phosphorylation of Erk.  
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On the other hand, the inability to attenuate an inflammatory response predisposes the 
organism to chronic inflammatory disease, carcinogenesis or autoimmune disease. For 
this reason, maintaining inflammatory balance is necessary. While, the importance of 
PAF in the immune system and immune responses is irrefutable, its seemingly bivalent 
role is still a focus of investigation. As previously discussed, PAF is known to mediate 
robust pro-inflammatory mechanisms both locally, such as urticaria and 
bronchoconstriction, as well as systemic anaphylaxis. With the development of a PAFR 
KO mouse, however, the role of PAF as an anti-inflammatory mediator has come to light. 
II. The immune system 
 Mammals have complex immune systems consisting of both pro-inflammatory as 
well as anti-inflammatory mechanisms, topics that require whole textbooks to cover in 
detail [1]. Inflammatory mechanisms are largely mediated by inflammatory effector cells, 
such as neutrophils, macrophages, cytotoxic T lymphocytes (CTLs) and many T helper 
subsets, through the release of inflammatory mediators, such as TNFα, interleukin-4 (IL-
4), and IFN-γ. On the other hand, anti-inflammatory mechanisms are mediated largely by 
regulatory T cells (Tregs), a subset of CD4+ T helper cells, through the release of anti-
inflammatory mediators, such as TGFβ, IL-10, and prostaglandin E2 (PGE2). These 
responses typically involve two main branches of the immune system, the innate and the 
adaptive immune system. Cytokines and chemokines orchestrate the mechanisms 
between these two branches. 
A. Cytokines and chemokines  
 In short, cytokines are proteins that signal between cells in the immune system 
and the rest of the body [37]. Most cells in the body can release cytokines to signal the 
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promotion or attenuation of inflammatory responses. Cytokines can activate and recruit 
cells, affect vasculature to promote or reduce swelling, and induce fever. As mentioned 
above, inflammatory cytokines include TNFα, IL-4, and IFN-γ, whereas anti-
inflammatory cytokines include TGFβ and IL-10. Moreover, cytokines can also be 
divided into Type 1, and Type 2 cytokines. Type 1 cytokines, such as IL-2 and IFNγ, 
promote cell-mediated immune responses. Type 2 cytokines, such as IL-10 and IL-4, 
promote humoral, or antibody-mediated immunity. Chemokines are chemotactic 
cytokines that induce cell motility of specific chemokine receptor-expressing cells toward 
a concentration gradient of the chemokine ligand. An example of this is the trafficking of 
CCR7+ dendritic cells to CCL19-releasing LNs following dendritic cell activation [38].  
B. The innate immune system 
 The most basic function of the immune system is the ability to distinguish 
between self and foreign organisms [39, 40]. While the adaptive immune system is 
responsible for identifying foreign proteins in the context of self, this is a relatively slow 
process taking up to a week to mount an immune response. The innate immune system, 
however, mediates responses within hours and is a critical first line of defense. By 24 
hours, the innate cells infiltrate the site of infection or damage, and begin clearance of 
damaged cells, noxious agents, and pathogens. During this process, some cells called 
antigen presenting cells (APCs) take up foreign proteins, process them, and present them 
to cells of the adaptive immune system over the course of several days to activate the 
adaptive immune response.  
 The innate system is classically composed of dendritic cells, macrophages, 
neutrophils, natural killer cells, eosinophils, basophils and mast cells (MCs). Of these 
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cells, dendritic cells and macrophages are the main APCs that present antigen to the 
adaptive immune system. Neutrophils, macrophages and natural killer cells are mostly 
involved in foreign body, apoptotic body and pathogen clearance. Eosinophils, basophils 
and MCs are responsible for promoting and sustaining pro-inflammatory mechanisms.  
 Innate cells are primarily activated and recruited by pathogen-associated 
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [41]. 
PAMPs are molecules, usually components of pathogen cellular structure, which are 
unique to a particular group of pathogens and thus help in differentiating host from 
pathogen. PAMPs have several specific receptors that they activate, which are called toll-
like receptors. A classical example is lipopolysaccharide that is a component of gram-
negative bacteria cell walls, binds toll-like receptor 4 [42]. DAMPs are typically host 
intracellular components that upon release, as a result of necrosis, cell damage or 
exocytosis, send a danger signal to the innate immune system signifying that pathogens 
or damaged cells need to be cleared. DAMPs activate several receptors that are a current 
topic of investigation. An example of a DAMP is HSP90, an intracellular protein 
chaperone that is released upon cell stress and activates CD91 on innate cells [43]. 
 Recently, the identification of an innate cell population with immunosuppressive 
potential has been revealed [44, 45]. Originally discovered in the 1960s in tumor models, 
myeloid-derived suppressor cells (MDSCs) appear to be a heterogenous population of 
cells that contribute to the immunosuppressive branch of the innate system [46]. They are 
primarily known for promoting tumorogenesis and metastasis [47, 48], but have been 
shown to have effects in other systems [45]. While lacking markers for T cells, B cells, 
NK cells and macrophages, MDSCs are typically characterized as antigen Gr1+ CD11b+ 
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in mice and CD14–CD11b+ in humans [44]. MDSCs have been shown to interact closely 
with other innate cells, such as MCs, but also with the adaptive immune system [49-51].  
C. The adaptive immune system 
 While the innate immune system is limited to recognizing PAMPs and DAMPs, it 
is estimated that the adaptive immune system is able to recognize over 2.5x107 different 
antigens, or specific peptide sequences [52]. The process of identifying pathogen antigens 
and mounting an immune response takes time, but results in a specific and efficient 
response. The adaptive immune system consists of two main cell types, B cells, which 
produce antibodies, and T cells, which mediate and assist cell mediated immunity. Over 
the course of several days following infection, APCs will take up proteins and after 
receiving an inflammatory signal, will migrate to draining LNs where B and T cells await 
activation.  
 B [53] and T [54] cells are activated when their receptors (BCR and TCR, 
respectively) bind a specific antigen. In the LN, B and T cells express unique receptors 
that are specific to a particular antigen. Following presentation of the antigen on major 
histocompatibility complex (MHC) molecules by APCs, T cells expressing a TCR 
specific to the antigen being presented will be activated and rapidly proliferate, resulting 
in clonal expansion of antigen-specific T cells. Simultaneously, antigen-specific B cells 
will recognize soluble antigen on their BCR, receive a primary activation signal and 
internalize this complex. The antigen taken up is then presented to T cells. A cognate 
interaction occurs when antigen-specific mature T cells meet a matching activated B cell 
by virtue of the presented surface antigen. This interaction results in the secondary 
activation signal to B cells to initiate the production and release of soluble antibodies. 
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The antibodies can then neutralize pathogens by opsonization, decrease motility, or cell 
lysis by the activation of the complement system. Following this secondary activation, B 
cells can also be instructed to produce different isotypes of antibodies, each which have 
well defined functions. IL-4 for example, induces B cells to undergo class switching to 
IgE. 
 As the process of B cell activation and antibody production ensues, two main 
types of T cells also mediate the immune response: CD8+ CTLs [55] and CD4+ T helper 
(Th) [56] cells. Once activated, CTLs are responsible for direct cell mediated immunity. 
They travel to the site of insult and survey cells for the presence of the particular foreign 
antigen to which they were activated. If they find a cell that presents this peptide in the 
context of MHC, they will release cytotoxic granules that will induce apoptosis. In 
parallel, Th cells are mostly responsible for supporting various branches of the immune 
response. To tailor to different inflammatory scenarios, various subsets of Th cells 
develop that secrete different cytokines depending on the cytokine microenvironment. 
Historically, Th subsets were classified as Th1, Th2 and Tregs. Type 1 cytokine-
producing Th1 cells, promote Type 1 immune responses or cell mediated immunity. They 
promote the expansion and activation of CTLs as well as recruitment of macrophages and 
neutrophils. Type 2 cytokine-producing Th2 cells, promote Type 2 or humoral immune 
responses. They induce the activation of B cells to produce soluble antibodies, and induce 
mast cell and eosinophil recruitment. As mentioned earlier, another subset of Th cells are 
Tregs, which mediate anti-inflammatory responses by the secretion of IL-10 and TGFβ. 
They inhibit T cell proliferation and promote wound healing. Since the definition of Th1, 
Th2 and Treg cells, many other subsets of Th cells have been identified and named 
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according to the interleukin that they express, such as Th9 and Th17, or their role, such as 
T follicular helper cells, Tfh.  
 After the necrotic tissue, noxious stimulus, or pathogen is cleared a normal 
immune response is attenuated [57, 58]. During this process, many immune cells 
succumb to apoptosis due to the regression of prosurvival and proliferative signals and 
cytokines. Apoptotic neutrophils, necrotic cells and remaining pathogens are cleared 
mostly by tissue resident macrophages. Over 90% of the antigen-specific T cells and B 
cells also perish by apoptosis. Some of the remaining lymphocytes continue to circulate 
for some time, while others receive signals to become endowed with longevity as 
memory T and B cells. These memory cells serve to quick start immune responses should 
the host encounter this antigen again, reducing the time to ramp up adaptive immunity to 
a couple of days. Finally, some B cells will maintain some antibody production that will 
circulate in the blood for some time. IgE antibodies produced will bind specific IgE-
receptors, FcεR, on basophils and MCs.  
III. The mast cell  
 Mast cells were discovered by Paul Ehrlich in the late 1870s. He described 
“mastzellen” as granulated aniline staining cells that resided in perivascular connective 
tissues [59-61]. Since then, MCs have been found to be long-lived hematopoietic cells 
that serve as sentinels in interfaces with the environment and circulatory system to 
initiate allergic responses upon recognition of pathogenic stimuli. In particular, MCs are a 
necessary part of the immune system to clear toxins, and fight off parasitic, e.g. helminth, 
and bacterial infections [62]. Most notably, however, MCs are also responsible for 
seasonal allergies in millions of people worldwide [63, 64]. MCs store prepackaged 
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vesicles containing inflammatory mediators, such as histamine, serotonin and proteases, 
which are released following MC activation. MCs can also synthesize and secrete 
cytokines and chemokines, in addition to the production of eicosanoids, such as 
prostaglandins and leukotrienes. While their pro-inflammatory role is well documented, 
lately their role as anti-inflammatory mediators is a current topic of investigation.  
A. Mast cell development and trafficking 
 MCs originate in the bone marrow from a common hematopoietic stem cell 
progenitor [65]. Common myeloid progenitor cells will differentiate from this stem cell 
pool and finally give rise to MC progenitors. These stem cell and MC progenitor 
populations expand in response to the activation of the stem cell factor (SCF) receptor, 
cKit. These MC progenitors exit the bone marrow and circulate the blood until they 
extravasate into tissues where they will mature into MCs that are characteristic of that 
tissue, while still maintaining cKit expression. Integrins and chemokine signaling largely 
regulate this migration. An example of this is the recruitment of MC progenitors to the 
gut, where CXCR2 was found to be necessary [66]. Once in the tissue, MCs have been 
estimated to have a life span of over 9 months [67]. This process of tissue maturation is 
advantageous for transplant models, where in vitro-derived MCs can be transplanted to 
reconstitute tissues with mature populations of tissue resident MCs. Mast cell 
reconstitution in MC-deficient mice has been well characterized and utilized in the 
literature [68-71]. Historically, it was thought that tissue-resident MCs remained in their 
tissues for the remainder of their life span. Recent evidence, however, suggests that MCs 
can migrate to nearby tissues after activation [72-74]. Their role after secondary 
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migration is a topic of current investigation and MC reconstitution models have proven to 
be useful.  
 There are different MC types whose characteristics depend on the tissue where 
they mature. Typically, MCs are classified depending on the contents of their granules. In 
mice, there are connective tissue MCs and mucosal MCs [75]. Connective tissue MCs, 
which include serosal MCs and skin MCs, typically have high granule density that 
contain heparin, histamine and MC proteases such as mMCP-4 and -5 (chymases), and 
mMCP-6 and -7 (tryptases). Mucosal MCs have low granular density that contain low 
levels of histamine and heparin, but high concentrations of mMCP-1 and -2 (chymases). 
Similarly, in humans, MCs are also divided into two groups characterized by their 
granular content: Tryptase+ MCs and Tryptase+ Chymase+ MCs. Interestingly, there has 
been some evidence pointing out the plasticity of MCs, where MC subtypes could 
become another MC type. An example of this was shown where heparin+ peritoneal MCs 
lost their heparin expression in vitro, but regained this function after transplantation [76]. 
B. MC signaling pathways 
 MCs function as signaling relays that translate incoming stimuli and orchestrate a 
myriad of responses through the release of secondary mediators. MCs have been shown 
to express an exhaustive list of receptors that include: Fc receptors, toll-like receptors, 
GPCRs (e.g. PAFR, histamine receptors, prostaglandin receptors), transient receptor 
potential cation channels, interleukin receptors, chemokine receptors, and intracellular 
receptors. Classically, mast cells are known to bind the Fc (fragment crystallizable) 
domain of circulating IgE antibodies on surface FcεRs. These bound IgE antibodies serve 
as sensors to detect antigens of possible pathogens. This makes Fc receptors versatile to 
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mediate responses to a large number of different antigens. When these surface bound IgE 
antibodies on MCs are cross-linked by an agonistic multivalent antigen, they cluster 
FcεRs. While, FcεRs lack intrinsic tyrosine kinase activity, secondary kinases are crucial 
to transphosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs) on 
coupled neighboring receptors [77]. Identified secondary kinases Hck, Fyn, Syk and Lyn 
are Src family kinases. These Src kinases mediate the phosphorylation of ITAMs on 
FcεRs as well as the activation and deactivation of tertiary signal transduction pathways. 
This activation finally culminates in calcium mobilization, activation of gene 
transcription and translation, the synthesis and release of protein and lipid mediators, and 
MC degranulation. The rapid release of granule-stored mediators is the orchestration of 
calcium release and activation of actin, microtubule and SNARE (soluble N-
ethylmaleimide-sensitive factor attachment protein receptors) protein mechanisms [77-
79].  
C. MCs in physiology 
 Many of the granule contents released upon FcεR activation, induce potent pro-
inflammatory effects. As mentioned before, granule contents include amines (e.g. 
histamine, polyamines), proteoglycans (e.g. heparin), proteases (e.g. tryptases, chymase, 
cathepsin, granzyme B, carboxypeptidases), lysosomal enzymes, and cytokines (e.g. 
TNF, FGF, IL-4 and SCF) [80]. These released mediators induce local leukocyte 
recruitment and infiltration, vasodilatation, and edema. Systemic activation of MCs, 
however, can result in anaphylactic responses. Proper MC activation can mediate 
successful countermeasures against infection; however, improper MC activation to 
innocuous stimuli like pollen, can result in allergic hypersensitivity reactions, such as 
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seasonal allergies. Interestingly, MCs have been shown to have more direct effects on the 
adaptive immune system. For instance, MC granules have been shown to travel through 
the lymphatic system to deliver granule contents to draining LNs [81]. In addition to 
mediator release, MC migration to draining LNs has been found to be important to induce 
immune responses [72]. MCs can phagocytose, express MHC-II and present antigen to 
influence T cell activity [82-85]. This evidence suggests that MCs can have non-
canonical effects on the immune system. In fact, MCs have also been shown to attenuate 
immune responses [70].  
D. MCs in immunosuppression 
 The suppressive effects of MCs on immune responses have some precedence [86, 
87]. MC IL-10 release has been shown to limit pathology from contact dermatitis and 
chronic UVB irradiation [88]. MCs have been shown to contribute to transplant tolerance 
[89]. Additionally, experiments have demonstrated that MCs will induce Treg 
differentiation via TGFβ when cocultured with naïve T cells [90], and augment the 
suppressor activity of MDSCs [50, 91]. Still, it seems that MCs can fine tune immune 
responses even by transiently attenuating Treg function through histamine receptor H1 
activation [92], but inducing Treg recruitment by H4 receptor activation [93]. 
Interestingly, MCs have been shown to attenuate anti-tumor immunity to promote skin 
tumorognesis [94, 95] and mobilize Tregs and MDSCs in the tumor microenvironment 
[96]. 
IV. Melanoma 
 In the United States, one in five people will develop a form of skin cancer during 
their lifetime [97]. Less than 1% will develop melanoma skin cancer; however, 
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melanoma claims more than 70% of skin cancer-related deaths [98]. Surgical excision 
cures virtually all melanoma in situ. Still, a survival rate of less than 15% for metastatic 
melanoma reflects deficiencies in current treatments [98]. Recent clinical reports show, 
however, that immunotherapies hold promise for treating metastatic melanoma [98-103]. 
Yet, these therapies depend on a competent immune system.  
A. Pathophysiology of melanoma 
 There are two main predispositions for melanoma: sunlight exposure and genetic 
predisposition [104]. Sunlight exposure poses a threat due to the mutagenic effects on 
sunlight, particularly in its ability to form pyrimidine dimers in DNA [104]. These insults 
can propagate further mutagenesis in DNA that can eventually lead to cancer, especially 
if the genes involved are tumor suppressors or oncogenes [104]. It is well recognized that 
light skinned individuals are at greater risk for developing skin cancers, including 
melanoma. Moreover, sun exposed skin, such as upper back skin in men, and back and 
leg skin in women, are at greater risk for developing melanoma [104]. Still, the 
correlation between sunlight and carcinogenesis is not simple, for people occasionally 
develop melanoma in areas not associated with heavy sunlight exposure. Recently, 
however, it was found that heavy sunburns early in life might be of greater significance 
for melanoma formation [104]. 
 Studies have estimated that greater than 10% of melanoma cases are familial 
[104]. In the case of hereditary and spontaneous melanomas two main signaling pathways 
are usually involved, either mutations diminishing tumor suppressors or mutations 
enhancing oncogenes. Approximately 40% of familial melanoma cases are found to have 
mutations in the CDKN2A gene, which encodes a complex locus of three different tumor 
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suppressors [104]. These tumor suppressors, p15/INK4b, p16/INK4a, and p14/ARF, 
ultimately activate other tumor suppressors, such as p53, which downregulates the 
activity of MDM2, a strong oncogene. The other group of familial melanoma cases 
consists of mutations promoting oncogenes. In particular, a large majority of these tumors 
have activating mutations in the RAS signaling pathways. For instance, 70% of 
melanoma tumors contain activating mutations to the oncogene BRAF, one of the targets 
of RAS [104]. As such, BRAF inhibitors are currently being developed and some 
currently available are first line of treatment.  
B. Prognosis and current treatments 
 While surgery is the first line of treatment for melanoma in situ with great 
prognosis, therapeutic options for metastatic melanoma are limited. Metastatic melanoma 
is tolerant to chemotherapy and radiation therapy [105, 106]. Metastatic melanoma poses 
a grave prognosis due to a higher mortality rate, albeit less prevalent, than non-melanoma 
skin cancer. In 2010, the American Cancer Society estimated a disturbing 68,000 new 
melanoma diagnoses, whereas 8,700 deaths were calculated (www.cancer.org/statistics). 
Sadly, while incidence rates have declined slightly, medical advances prove inadequate to 
taper the raising mortality rate of melanoma [105-108]. As such, novel therapeutic 
approaches merit attention.  
 Currently, immunotherapies show promising results in the clinic, which include 
the use of cytokines, such as interferon, IL-2, IL-15, IL-21 and CTLA-4 (Cytotoxic T-
Lymphocyte Antigen-4) inhibitors [109-112]. Adoptive transfer of melanoma specific T 
cells has also been used [100], as well as immune sensitizers, such as imiquimod. Thus, 
investigation of the interplay between melanoma and the immune system is relevant. 
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Recently, the use of oncogene-targeted therapy has been a growing field. BRAF 
inhibitors, such as vemurafenib, and tyrosine kinase inhibitors, such as imatinib, can also 
be used in tandem with immunotherapies.  
C. Chemotherapy as a therapy and oxidative stressor 
 The mechanisms by which melanoma is resistant to chemotherapy is a topic of 
ongoing study. Still, chemotherapy has a place as a last line of recourse. While systemic 
administration of current chemotherapeutics, such as etoposide or dacarbazine, may be 
useful to shrink tumors for surgical resection, they typically are not curative alone. The 
systemic doses needed to overcome resistance would be extremely toxic to patients. 
Fortunately for some patients with metastatic disease contained to a single limb, isolated 
limb perfusion (ILP) chemotherapy can be used [99, 113, 114]. By cannulating the artery 
and veins supplying blood to a limb, an external pump can be used to deliver high dose 
chemotherapy to the isolated limb. ILP has been used with significant curative success in 
these patients. This method is not without drawbacks, however. Due to their nature, 
chemotherapeutics are known to be cytotoxic, immunosuppressive and strong oxidative 
stressors. The ROS generated following ILP could diffuse systemically after treatment. 
While chemotherapy could be immunosuppressive via the cytotoxicity of proliferative 
hematological stem cells, I hypothesize that ROS generated by chemotherapy could also 
lead to systemic immunosuppression following a PAFR-dependent mechanism. Such an 
immunosuppressive mechanism from ROS is a current topic of investigation in 
immunosuppression mediated by ultraviolet light.  
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V. Ultraviolet light mediated systemic immunosuppression 
 The therapeutic properties of sunlight have long been recognized and have been 
used in the clinic. In particular, ultraviolet light B (UVB) is commonly used in the clinic. 
UVB is a component of sunlight, and is characterized as light in the wavelengths between 
315-280 nm, whereas the visible spectrum is made up of wavelengths between 760 – 400 
nm [115]. In the clinic, UVB has been used to treat vitiligo and psoriasis, both 
autoimmune diseases in which the immune system is self-reactive to melanocytes and 
keratinocytes, respectively [116, 117]. These phototherapies are particularly effective 
largely due to their immunosuppressive effects, which have been an ongoing topic of 
research. To date, several pathways have been identified that mediate the 
immunosuppressive effect of UVB. DNA, Cis-urocanic acid (cis-UCA), and PAF are 
among these pathways [118, 119].  
A. Contact hypersensitivity models 
 Several models have been proposed to study the immunosuppressive effects of 
UV light. The most common in vivo model for the field is a contact hypersensitivity 
(CHS) model. CHS is a Type IV hypersensitivity, also known as delayed- or cell-
mediated hypersensitivity, which is a type of reaction that is classically seen with poison 
ivy reactions. In contrast to type I hypersensitivities, such as seasonal allergies that are 
antibody-mediated, CHS reactions are mediated largely cell-mediated both by CD8+ 
CTLs and CD4+ Th1 cells. A typical CHS reaction in mice has two phases, a 
sensitization phase and a challenge phase (Figure 6).  
 During the sensitization phase, the antigen is introduced either topically or 
subcutaneously. Over the course of 5-9 days, APCs in the skin, Langerhans cells in the 
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epidermis and dendritic cells in the dermis, will uptake the antigen, migrate to draining 
LNs, and process and present the antigen on surface MHC molecules. In the LN, APCs 
present the antigen to both CD8+ and CD4+ T cells, where antigen specific cells will be 
activated and mature into CTL and various T helper cells, respectively. Most of the CD4+ 
T cells will polarize and differentiate into Th1 cells that promote cell-mediated immunity 
by producing Type 1 cytokines, such as IL-2 and IFNγ. IL-2 is particularly important for 
the expansion of the activated CTL population to promote inflammation and clearance of 
the noxious antigen. Some CD4+ T cells will also differentiate into Tregs, whose role it is 
to keep the inflammatory response in check by attenuating CTL activity by the release of 
TGFβ and IL-10. Toward the end of the sensitization phase, the antigen will be cleared 
and some of the activated T cells will develop into memory cells.  
 After the sensitization phase, the mice are then challenged with the same antigen, 
typically on a site different than the site of sensitization. During the course of 24 hours, 
APCs will present the antigen in draining LNs and reactivate memory T cells. This will 
lead to a quicker and more robust expansion of CTL populations than in the sensitization 
phase. These cells will then infiltrate the site of challenge and mediate a large immune 
response that promotes inflammation of the tissue, which can be quantitated. This model 
is useful to quantitate the effect of various treatments on cell-mediated immune 
responses. In fact, it is well documented that UV irradiation on the dorsal skin of mice 
before the sensitization phase significantly attenuates the subsequent antigen challenge 
[119]. This decrease in swelling is a measure of the immunosuppressive effects of UV 
light.  
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Figure 6. Mechanism of contact hypersensitivity reactions. 
During the first exposure to an allergen, the immune system will become sensitized to 
the particular antigen in a process called sensitization. Hapten allergens, like DNFB, 
will bind proteins in the skin which are then taken up by antigen presenting cells 
(APCs) in the skin. The allergen will also induce activation of keratinocytes, MCs and 
fibroblasts in the skin, leading to the release of pro-inflammatory mediators. The 
release of these pro-inflammatory signals will induce the recruitment of PMNs and 
macrophages, as well as the migration of dendritic cells to LNs. Over the course of the 
next five days, APCs will present the allergen antigen to CD4+ and CD8+ T cells 
leading to their activation and expansion. Activated CD4+ T cells will differentiate 
into various T helper subsets, including Th1 cells which by the release of IFNγ and 
TNFα promote CD8+CTL  cell-mediated inflammatory mechanisms, and Tregs which 
suppress the inflammatory response. These activated T cells will then migrate to the 
original site of sensitization over the course of days 6-9, and mediate inflammatory 
mechanisms by the release of  IFNγ and TNFα. For CHS experiments, a second site is 
exposed to the allergen to induce a challenge response nine days after sensitization. To 
do so in mice, ears are measured, one ear is treated with the allergen DNFB, and the 
other is treated with vehicle. After 24 hours, ears are measured again. Over the course 
of these 24 hours, the adaptive immune system will mount a robust inflammatory 
response in the allergen treated ear via the infliltration of CTLs and Th1 cells.  
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B. DNA and Cis-UCA 
 The carcinogenic properties of UV light have long been recognized, due in part to 
the resulting pyrimidine dimer formation and subsequent mutagenesis in DNA. Work by 
Kripke, and collaborators, demonstrates that DNA can also act as a photoreceptor to 
initiate the immunosuppressive effects of UV light [120]. Using a CHS model, they 
found that if DNA repair pathways were activated after UV irradiation, the DNA damage 
was resolved along with the immunosuppressive effects of UV.  Another photoreceptor 
that has been found is trans-urocanic acid, which is a deamination product of histamine 
found abundantly in the stratum corneum [118, 119, 121]. Upon UV irradiation, trans-
urocanic acid isomerizes into cis-urocanic acid, which has been shown to mediate 
systemic immunosuppression in mice [122]. In fact, tape stripping to remove the stratum 
corneum in mice has been shown to inhibit the immunosuppressive effects of UV [123], a 
process that can be rescued by injection of cis-urocanic acid [122]. The ability of UV to 
isomerize urocanic acid and induce pyrimidine dimer formation is largely due to its 
properties as ionizing radiation. As ionizing radiation, however, UV can also induce ROS 
formation.  
C. Free radicals, lipid oxidation and PAF 
 Due to its high-energy electromagnetic properties, UVB light has been shown to 
excite oxygen and water to form free radicals. For example, ground state triplet oxygen 
(3O2) can be activated to singlet oxygen (1O2) or superoxide anion (O2•-). Superoxide can 
then be reduced to hydrogen peroxide (H2O2) spontaneously or by superoxide dismutase. 
Hydrogen peroxide can then be reduced further to form hydroxyl radical (OH•-) by heavy 
metals in solution (e.g. Fe2+) via the Fenton reaction. These ROS while transient are 
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highly reactive and propagate radical formation in solution. In the skin, ROS can react 
with any number of targets including carbohydrates, nucleic acids, proteins, and lipids. 
Some of the most abundant targets are phospholipids that make up outer and organelle 
membranes in cells. As explained above, these ROS can induce the formation of PAF-
like species by oxidizing GPCs in cell membranes.  
 PAF, as well as ox-GPCs, have been identified as primary mediators of the 
immunosuppressive effects of UVB.  First, Ullrich and colleagues demonstrated that 
exogenous PAF is sufficient to activate systemic immunosuppression [16]. Later on, our 
lab demonstrated that UVB generates PAF-like phospholipids [26] and that these 
phospholipids induce systemic immunosuppression.  Work in this field has shown that 
systemic administration of antioxidants can attenuate the immunosuppressive effect of 
UVB on CHS as well as the generation of ox-GPCs in vitro. Furthermore, structural 
identification of many ox-GPCs induced by UVB irradiation has been made possible by 
mass spectrometry analysis. The ability of UVB to act as an oxidative stressor to induce 
the formation of PAF-like species has also been demonstrated in other oxidative 
stressors. Such other oxidative stressors that induce PAFR-dependent systemic 
immunosuppression are cigarette smoke, jet fuel and photodynamic therapy [118, 119]. 
Mechanistic studies for PAFR-mediated immunosuppression are ongoing, but several 
mediators of PAFR-mediated immunosuppression have been identified.  
D. Mediators involved in PAFR-mediated immunosuppression 
 In recent years, Tregs have been shown to mediate immunosuppression. Growing 
evidence suggests that Tregs are a necessary component for UVB-induced immune 
suppression [118, 119]. Recent studies by our lab have shown that Tregs play a crucial 
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part in the PAFR-dependent pathway of immunosuppression [24, 25]. In fact, this effect 
can be attenuated by the treatment with Treg-depleting antibodies. Tregs have been 
shown to increase in populations following CPAF and UV treatment. Furthermore, UV-
generated Tregs can be adoptively transferred to a naïve organism to establish tolerance 
[124]. IL-10, one of the primary mediators of immunosuppression released by Tregs, has 
also been implicated in this pathway. IL-10 neutralizing antibodies significantly reduce 
the amount of PAFR-dependent immune suppression. Another cell type that has been 
implicated in this pathway is the mast cell [124-127]. 
 Upon activation, mast cells release a number of immune modulators by de novo 
synthesis of mediators, or degranulation of pre-made vesicles. In addition to expressing 
the PAFR, MCs have been shown to release histamine and prostaglandins, as well as an 
upregulation in a number of chemokines and chemokine receptors upon activation [65, 
72, 128, 129]. Interestingly, while wild type mice demonstrate sensitivity to PAF-induced 
systemic immune suppression, this sensitivity is ablated in mast cell deficient mice. 
Reconstitution of dermal WT MCs, however, restores the immune suppressive response 
to PAF. Additionally, work by Ullrich and collaborators demonstrate that MC migration 
to draining lymph nodes (LN), following systemic PAF treatment, is necessary for PAF-
induced immunosuppression [73, 74]. Furthermore, this MC migration and subsequent 
immunosuppression was attenuated using a specific inhibitor to the CXCL12 chemokine 
receptor CXCR4, AMD3100 [73, 74]. This evidence suggests that MC CXCR4 is 
necessary to mediate MC migration in PAF-induced immunosuppression. This migration 
to lymph nodes could allow for direct MC and T cell interactions for the possible 
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generation and activation of Tregs. The mechanisms by which CXCR4 and CXCL12 are 
orchestrated are still a topic of investigation. 
 One proposed mechanism of action involves the role of prostaglandins, in 
particular PGE2. As mentioned previously, prostaglandins are synthesized from 
arachadonic acid released from GPCs by the cleavage of PLA2. This free arachidonic acid 
is then converted to PGG2, by the prostaglandin synthase activity of COX, and reduced to 
PGH2 by the peroxidase activity of COX. PGH2 can then be converted to various other 
prostaglandins by the activity of other prostaglandin synthases, such as PGE2 by 
prostaglandin E synthase. There are classically two isoforms of COX, the constitutively 
active COX-1 and the inducible COX-2. One of the main differences between COX-1 
and COX-2 is that COX-2 has a greater binding affinity for PGES and generally increases 
the production of PGE2, PGD2, and PGF2α. A significant body of work has demonstrated 
that UVB and PAF can induce the expression of COX-2, and that it is necessary for the 
subsequent immunosuppression [24, 25, 130]. For instance, there is evidence that 
systemic administration of COX-2 inhibitors can attenuate the immunosuppressive 
effects of UVB [25]. Additionally, PGE2 injection has been shown to upregulate CXCL12 
in lymph nodes [73]. Finally, it has been shown using small molecule agonists and 
antagonists that PGE2 receptor EP4 is necessary for the immunosuppressive effects of 
UV light [131]. 
VI. Summary, recent work and current hypothesis 
 Studies in the field, including our own, have demonstrated that various 
environmental oxidative stressors are immunosuppressive. While mechanistic detail of 
this process is lacking, a major contributor to this immunosuppression is the activation of 
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the PAFR. It was recently found that the immunosuppressive effects of UVB can enhance 
melanoma tumor growth in vivo and that this effect is PAFR-dependent [25]. Thus, I 
suspect that pro-oxidative melanoma therapies, in particular chemotherapeutics, such as 
melphalan and etoposide, could have similar effects due to their nature as oxidative 
stressors. Thus, this work has two aims. The first aim is to investigate the possible role of 
PAF in chemotherapy-induced immunosuppression. The second aim is to further 
illuminate the mechanism of PAF-induced immunosuppression. The work in Chapter 3-I 
was carried out to determine if PAFR agonists could be made at high-dose chemotherapy 
in ILP chemotherapy. I hypothesized that ox-GPCs generated by IPL chemotherapy 
meadiate systemic immunosuppression leading to greater tumor growth of a second 
tumor.  
 Preliminary studies demonstrated that MC-deficient mice were resistant to PAF-
induced increases in tumor growth. Furthermore, MCs have been shown to be necessary 
for UVB-induced immunosuppression [68]. Thus the second aim of this work, in Chapter 
3-II, is to investigate the role of the MC in PAF-induced systemic immunosuppression 
and the mechanism by which MC mediate effects on the immune system. I hypothesize 
that the MC PAFR is necessary for PAF-induced immunosuppression and that MC PAFR 
activation promotes systemic immunosuppression in a process involving MC-derived 
mediator release. 
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Chapter 2: Materials and Methods 
I. Chemotherapy induces systemic immunosuppression via the generation of 
PAFR agonists 
A. Reagents and cells 
 Chemicals were purchased from Sigma-Aldrich unless indicated otherwise. Anti-
CD25 and isotype antibodies were from BioXcell (West Lebanon, NH). SK23MEL and 
B16F10 melanoma cells were obtained from ATCC and were grown in DMEM high 
glucose supplemented with 10% fetal calf serum as described previously [25]. Plated cell 
lines were allowed to proliferate to ~80% - 90% confluency in 10 cm petri dishes, and 
washed with Hank's Balanced Salt Solution (HBSS) three times, then incubated with 2 
mL of warm (37°C) HBSS containing 10 mg/mL fatty acid-free BSA and 2 µmol/L of 
serine hydrolase inhibitor pefabloc. Before the addition of chemotherapeutic agents or 
DMSO (0.5%) vehicle, in some experiments, cells were preincubated with antioxidants 
for 60 minutes. Incubations were quenched by adding of 2 mL of methanol (0°C) 
followed addition of dichloromethane, and then lipids were extracted as described [24, 
26, 132].  
B. Mice 
 Wild-type female C57BL/6 (PAFR-expressing; age 6–8 weeks) were obtained 
from the Charles River Laboratories. C57BL/6 age and gender matched PAFR–deficient 
(PAFR KO) mice were used for experiments and, generated as previously described [35], 
were obtained from Prof. Takao Shimizu (University of Tokyo Department of 
Biochemistry, Tokyo, Japan). FoxP3-EGFP reporter mice [133] that were obtained from 
JAX, and FoxP3-EGFP mice that were crossed with PAFR KO mice were also used in 
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some experiments. No difference was observed between PAFR KO and PAFR KO 
Foxp3-EGFP mice in these experiments. Immunodeficient NOD.CB17-PrkdcSCID/J 
(Common name: NOD SCID) mice were obtained from the Indiana University Simon 
Cancer Center Core facility. In antioxidant experiments, mice were given vitamin C-
enriched chow (10 g/kg; Research Diets, Inc.) and bottles of 5 mM N-acetylcysteine 
(NAC) in water ad libitum for 10 days before and during intratumoral chemotherapy 
injections, until the end of the experiment similar to previous studies [25, 132]. All mice 
were housed under specific pathogen-free conditions at the Indiana University School of 
Medicine. All procedures were approved by the Animal Care and Use Committee of 
Indiana University School of Medicine.  
C. Measurement of PAFR agonists  
 The presence and concentrations of PAFR agonists in lipid extracts from treated 
melanoma tumors/cells or IPL perfusates were measured by measuring intracellular Ca2+ 
mobilization in response to treating PAFR–expressing KBP cells and PAFR-null KBM 
with isolated lipid extracts, as previously described [130, 132]. In brief, KBP and KBM 
cells were incubated with a cell permeable fluorescent Ca2+-sensitive indicator, fura-2-
AM (4 µmol/L in HBSS without dye) for 90 minutes at 37°C. Cells were then washed, 
and resuspended in room temperature HBSS before use. Lipid extracts from treated 
cells/tumors, or ILP perfusates were added to Fura-2-loaded cells (1.0–1.5 X 106 cells/2 
mL) in a cuvette at 37°C under constant stirring. Volume of lipid extracts used to treat the 
cells was normalized to cell number, wet tissue weight, or 1/10th volume of perfusate. 
1µM CPAF and endothelin-1 (ET-1), dissolved in ethanol, were used as positive controls. 
Fura-2-AM fluorescence was measured in a Hitachi F-4010 spectrophotometer using 
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excitation and emission wavelengths of 331 and 410 nm, respectively. The influx of Ca2+ 
in cell suspensions was calculated as described previously [24, 130, 132] and plotted as 
percentage of maximal calcium flux induced by either CPAF or ET-1.  
D. Mass spectrometry studies 
 Mass spectrometry analysis was accomplished in collaboration with Prof. Robert 
Murphy at University of Colorado, by Kathleen Harrison. Lipid extracts from treated 
cells/tumors or ILP perfusates were subjected to mass spectrometry analysis using the AB 
Sciex triple quadrupole QTRAP 5500 mass spectrometer, equipped with a CTC-PAL 
autosampler and a Shimadzu HPLC as previously described [134]. Please see Published 
Supplementary Materials and Methods for details of instrument settings and 
characterization of the various species monitored [135].  
E. In vivo tumor growth studies 
 To determine whether intratumoral chemotherapy can affect melanoma tumor 
growth, 5 X 105 B16F10 cells, which inherently do not express functional PAFR [25], 
were injected subcutaneously into bilateral shaved dorsal hind flanks of  both WT and 
PAFR KO mice to give rise to two tumors. Tumor growth was monitored by measuring 
length and width of tumors at daily with digital calipers (Mitituyo). Tumor volume was 
then calculated by the equation: (major length X minor length2/2). Six days after tumor 
implantation and every third day thereafter, the tumor on the left flank was treated by 
injecting ~100 µL of either etoposide (36 mg/kg), melphalan (15 mg/kg), or PBS with 
0.5% DMSO vehicle. The therapeutic dose of etoposide and melphalan was empirically 
derived by performing pilot studies in WT mice using different doses of 
chemotherapeutic (n=3–5). To determine whether COX-2 inhibitors can modulate the 
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tumor growth effects of chemotherapy, SC-236 (200 ng), NS-398 (5 µg), or 100 µL PBS 
with 0.5% DMSO vehicle were injected intraperitoneally, concurrently with intratumoral 
chemotherapy at day 0 and every 3 days afterwards.  
F. Human isolated limb perfusion chemotherapy studies 
 In collaboration with surgeons Douglas S. Tyler and Paul J. Speicher from Duke 
University, as well as Christopher E. Touloukian at Indiana University, perfusate samples 
were obtained from subjects undergoing ILP regional melphalan chemotherapy for 
melanoma. During the procedure, aliquots of perfusate (8mL) were removed at various 
time points (after initiation of closed-circuit perfusion, after heating the core limb to 
40°C, and 15, 30, 45 and 60 minutes following initiation melphalan treatment) from the 
extracorporal circulation and mixed with equal volumes of ice-cold methanol and 
dichloromethane, after which lipids were extracted. The human studies were approved by 
the Indiana University and Duke University School of Medicine Institutional Review 
Boards.  
G. Statistical analysis  
 For all mouse studies, individual experiments contained at least four mice per 
experimental group and experiments were repeated at least once to verify reproducibility 
and to provide additional data for analysis. In collaboration with Indiana University 
statisticians Sandra K. Althouse and Susan M. Perkins, statistical differences were 
calculated using SAS Version 9.3. Tumor volume was calculated using the equation: 
(major length X minor length2/2). For murine studies, analysis was focused on the end of 
the study around days 14 to 18, where available. Shapiro–Wilk and the Levene tests were 
used to check the normality of data and equal variances and were found to be a 
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reasonable assumption in all cases. For in vivo and in vitro data, equal or unequal 
variance t tests were used to compare differences between two groups. For comparing 
differences between more than two groups, two-way ANOVA tests (with Welch 
approximation if the variances between groups were unequal) and post hoc Tukey-
adjusted pairwise tests. The data depicted represent mean values with SEM. Differences 
were considered statistically significant when the p value was less than 0.05 and trending 
but not significant when the p value was less than 0.10 but greater than 0.05. 
II. Mast cell-derived histamine and prostaglandins mediate IL-33 receptor 
dependent PAF-induced immunosuppression 
A. Reagents and cells  
 All chemicals were obtained from Sigma–Aldrich (St Louis, MO) unless 
indicated otherwise. COX-2 (NS-398 and SC-236) and TGF-β inhibitors (SB431542 and 
LY364947), and histamine EIA kit were obtained from Cayman Chemicals (Ann Arbor, 
MI). PGE2 EIA was obtained from R&D (Minneapolis, MN). qPCR reagents were 
obtained from Invitrogen (Carlsbad, CA). Primers for qPCR were obtained from IDT 
(Coralville, IA). Antibodies for western were obtained from Abcam (Cambridge, MA). 
Mast cells were obtained by culturing murine bone marrow in 10% FBS and IL-3 (10 
ng/mL, Peprotech, Rocky Hill, NJ) containing IMDM media for 4-8 weeks. Cell cultures 
contained mast cell populations (FcεR+, c-kit+) greater than 90% as measured by flow 
cytometry, using antibodies from eBioscience (San Diego, CA) and BD Biosciences (San 
Jose, CA). Cells used for in vitro studies were incubated in 1mL of 10% FBS containing 
IMDM media supplemented with 10 ng/mL of IL-3 in 12 well plates.  
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B. Mice 
 C57BL/6 (WT; Charles River Laboratories, Sulzfeld, Germany) and C57BL/6 
KitWsh/Wsh (Wsh; The Jackson Laboratory, Bar Harbor, ME) mice were obtained 
commercially. PAFR KO (from Prof. T. Shimizu, University of Tokyo, Tokyo, Japan) 
and HDC KO (from Dr. H. Ohtsu, Tohoku University, Miyagi, Japan) mice on a 
C57BL/6 background were kept under pathogen-free conditions. Bone marrow from 
Mcpt5-cre/Ptgs2flox/flox and Ptgs2flox/flox mice for mast cell transplantation were kindly 
provided by Dr. Garret FitzGerald (University of Pennsylvania, Philadelphia, PA). BoyJ 
mice were provided by the In Vivo Therapeutics Core (Indiana University School of 
Medicine, Indianapolis, IN). All mice were housed under specific pathogen-free 
conditions at the Indiana University School of Medicine. All procedures were approved 
by the Animal Care and Use Committee of Indiana University School of Medicine. 
C. MC PAFR functional assay 
 The presence of PAFR on BMMCs was determined by the ability of CPAF to 
induce an intracellular Ca2+ mobilization response in BMMCs. In brief, BMMCs were 
preloaded with the Ca2+-sensitive indicator, fura-2-AM (4 µmol/L in HBSS without dye) 
at 37°C for 90 minutes, washed, and resuspended in HBSS at room temperature before 
use. CPAF was then added to an aliquot of these cells (1.0–1.5 106 cells/2 mL) in a 
cuvette at 37°C with constant stirring. Fura-2-AM fluorescence was monitored in a 
Hitachi F-4010 spectrophotometer with excitation and emission wavelengths of 331 and 
410 nm, respectively. The Ca2+ influx in suspensions was calculated as described [24, 
130, 132].  
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D. Mast cell transplantation and contact hypersensitivity assay  
 MCs (106) were injected subcutaneously into two rows of four injections sites in a 
1 by 2 cm area on the shaved dorsal skin of 6-8 wk old Wsh or Wsh PAFR KO mice. 
After 6 weeks post-implantation, mice were used for experiments. For contact 
hypersensitivity, mice were either treated on shaved dorsal skin with vehicle, UVB (7.5 
kJ/m2), histamine (200 µg s.c.), or CPAF (200 ng i.p.). Five days post-treatment 25µL of 
0.5% DNFB (in 4:1 acetone/olive oil) was painted on shaved dorsal skin of mice. Nine 
days later ears were measured, and one ear was treated with 10µL of 0.5% DNFB while 
the other ear was treated with vehicle. After 24 hours, ear thickness was measured in 
these mice. The difference in ear swelling between DNFB and vehicle treated ears was 
normalized to the ear swelling in WT mice treated with vehicle. 
E. Histology 
 Dorsal skin samples or LNs from mice were formalin fixed for 24 hours before 
storage in ethanol. Specimens were paraffin embedded, sectioned and stained for MCs 
using acidified toluidine blue by the IUSM Histology Core [136]. MC numbers were 
quantified by counting ten high power fields (HPF, 600X). 
F. qRT PCR 
 Total RNA was extracted from treated mast cells using the RNAeasy kit (Qiagen). 
In brief, tissue was homogenized in RLT buffer containing 2-mercaptoethanol by 
pipetting and QIAShredder (Qiagen). Purified RNA was quantitated with the NanoDrop 
2000 (Thermo Fisher Scientific, Lafayette, CO). Reverse transcription of whole RNA 
was done using SuperScript cDNA synthesis kit (Invitrogen) with random hexamers. 
Quantitative RT-PCR was performed for Ptgs2, Hdc, Cxcr4, Il1rl1, and Tgfb1 against 
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Gapdh as the endogenous control using the ΔΔCt method on a Step One Real-Time PCR 
machine (Applied Biosystems, Foster City, CA). Each assay was performed in triplicate 
in a 10 uL reaction volume with Taqman Master Mix (SA Biosciences, Frederick, MD), 1 
ng cDNA, primers at 500 nM and probe at 250 nM.   
G. Flow cytometry 
 Cells (106) were taken from culture and plated in a 96-well plate in FACS buffer 
(PBS, 1%BSA, 0.1% NaN3) for staining. Cells were incubated with Fc Block (BD 
#553142) for 15 minutes and then stained with 1:100 or 1:200 concentrations of 
conjugated primary antibody for 30 minutes. Cells were then washed and resuspended in 
PBS to be stained with viability dye (eFluor 780) at a concentration of 1:1000 when 
applicable. For intracellular staining, unstimulated cells (unless otherwise noted) were 
fixed with IC Fixation buffer (#00-8222-49) or Fix/Perm Buffer (#00-5523-00) 
overnight, then washed and resuspended in Permeabilization Buffer (#00-8333-56). Cells 
were then stained with primary conjugated antibodies in Perm buffer for 30 minutes RT. 
Cells were then washed in Perm buffer and resuspended in FACS buffer. Cells were then 
resuspended to a concentration of about 105/100uL of cells in FACS buffer for analysis 
on the Invitrogen Attune Cytometer or the BD LSR II.  
H. Western Blotting and Densitometry 
 Cells (6x106) were harvested and washed twice with PBS. Cell pellets were then 
lysed with 150 uL of lysis buffer (1% Triton-X, 10mM Tris base, 150mM NaCl, 1% 
protease inhibitor mixture (Sigma); pH 7.4) and centrifuged for 15 minutes at 14K rpm at 
4°C. 120 uL of the supernatants were collected and their protein concentrations were 
measured by BioRad spectrophotometry methods. 30-100ug of protein with β-
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mercaptoethanol-containing reducing SDS sample buffer was then loaded into a 10% 
acrylamide gel and run for 45 minutes under a constant 400mAmps. Proteins were then 
transferred onto a nitrocellulose membrane for 1hr at a constant 100V at 4°C. The 
membrane was then cut and incubated with blocking buffer (5% powdered milk, 0.1% 
Tween-20, in PBS) for 2hrs RT or overnight at 4°C. Membranes were then incubated 
with the appropriate amount of antibody for 2 hr RT or overnight at 4°C. Membranes 
were then washed with TBST (20mM Tris, 150mM NaCl, 0.1% Tween-20) four times for 
5 minutes each before incubation with HRP-conjugated secondary antibody (1:5000) for 
30 min RT. Membranes were then washed with TBST four times for 5 minutes per wash 
before incubating the membranes with HRP-substrate (Millipore, Billerica, MA) for 1 
minute. Films were then exposed at serial time points and developed. Radiographs were 
then scanned, digitized and quantitated by pixel densitometry using ImageJ. Expression 
by densitometry was calculated by (pixel density of gene of interest/GAPDH pixel 
density) normalized to vehicle ratio.  
I. ELISA 
 Cells (3x106) were plated and treated for the described length of time. 
Supernatants were then collected from suspensions centrifuged at 400g for 10 minutes. 
For intracellular lysates, cell pellets were washed twice with PBS and then resuspended 
in 1mL of deionized water. This suspension was then frozen in liquid nitrogen and 
thawed in 56°C water two times. Samples were then centrifuged at 14K rpm to remove 
any particulates. These supernatants were then diluted according to the detectable range 
of the ELISA (usually 1:10 or 1:100) in media or analysis buffer.   
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J. Statistics 
 For all murine studies, individual experiments were performed using at least four 
mice per experimental group and repeated as necessary (at least once) to verify 
reproducibility and provide additional data for analysis. All statistical calculations were 
performed using Prism 6. For in vivo and in vitro data, one-way ANOVA (with the 
Bonferroni or Dunnett correction for comparing means to all other means or means to 
vehicle, respectively) was used to compare one group and two way ANOVA (with the 
Holm-Sidak correction to compare treatment means to vehicle) was used to compare 
multiple groups. The data represent mean values with SEM. Differences were considered 
statistically significant when the P value was less than 0.05.  
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Table 1. List of inhibitors 
Name Target Supplier Catalog # IC50 (µM) 
NS-398  COX-2 Tocris 0942 3.8 
SC-236 COX-2 Tocris 3919 0.005 
SB431542  TGFβR1 Cayman 13031 0.094 
LY364947 TGFβR1 Cayman 13341 0.059 
Table 2. List of antibodies 
Antibody Supplier Catalog # 
Fc Block BD Biosciences 553142 
CXCR4-PE eBioscience 12-0453-81 
FceR-PE eBioscience 16-5898-82 
CD117-APC eBioscience 17-1171-83 
TGFb/LAP-PE eBioscience 12-9821-80 
CD25 BioXcell BE0013 
CD25 BioXcell BE0012 
HDC Abcam ab37291 
COX-2 Abcam ab62331 
Table 3. List of Taqman Primer Assays 
Gene Supplier Assay ID 
Ptgs2 IDT Mm.PT.56a.14196835 
Hdc IDT Mm.PT.58.30065020 
Cxcr4 IDT Mm.PT.58.41597935 
Tgfb1 IDT Mm.PT.56a.11254750 
Il1rl1 IDT Mm.PT.58.11610831.g 
Gapdh Applied Biosystems 4352932E 
Table 4. List of genotyping Primers 
COX-2 KO Primers Supplier Sequence 
Forward IDT TGA GGC AGA AAG AGG TCC AGC CTT 
Reverse IDT TTT GCC ACT GCT TGT ACA GCA ATT 
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Chapter 3: Results 
I. Chemotherapy induces systemic immunosuppression via the generation of 
PAFR agonists 
A. Melanoma cells treated with chemotherapeutics generate PAFR agonists  
 Due to the fact that PAF is a lipid-derived molecule, which was first described as 
an activity having the ability to elicit platelet aggregation, measuring PAF concentrations 
or characterizing ox-GPCs is not straightforward. Thus, both a quantitative assay and a 
functional assay can be used to measure PAFR agonist concentrations. The quantitative 
assay is mass spectrometry through which, by the help of our collaborator Prof. Robert 
Murphy at University of Colorado, particular PAFR agonists in a sample can be 
characterized and quantitated. A Ca2+ mobilization assay can also be used as a functional 
read out to determine the ability of samples to activate the PAFR. This method was first 
developed in 1998 [130]. In short, a PAFR-negative human epidermal cell line (KB) was 
stably transduced with either the human PAFR to form KBP cells, or control MSCV2.1 
vector to form PAFR-null (KBM) cells. Binding studies using radiolabeled PAFR 
antagonist WEB2086 revealed the presence of PAFR protein. Further characterization of 
these two cell lines demonstrated that treatment with CPAF would induce intracellular 
Ca2+ release and IL-8 production in KBP cells that can be measured by fluorimetry and 
ELISA, respectively. To measure intracellular Ca2+release, cells are loaded with Fura-2-
AM for 2 hours and fluorescence is measured immediately after treatment using a 
spectrofluorimeter [130].  
 Thus, to determine whether chemotherapeutics generate PAFR agonists in 
melanoma treatment, B16F10 melanoma cells were incubated with various 
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chemotherapeutics currently used for the treatment of melanoma for one hour. Lipid 
extracts were isolated from these cells, which contain any generated PAF and ox-GPCs, 
using standard organic separation techniques [137]. To test for the presence of any PAFR 
agonists in these lipid extracts, Ca2+ mobilization in Fura-2 loaded KBP and KBM cells 
was measured in response to treating the cells with aliquots of lipid extracts. Lipid 
extracts from B16F10 cells treated with etoposide activated calcium release in KBP 
(Figure 7A), but not KBM (Figure 7B) cells, suggesting the presence of PAFR-agonists 
in these extracts. Figure 7A shows examples of Ca2+ measurements from KB cells treated 
with controls, or lipid extracts from vehicle or etoposide treated melanoma cells. 
Endothelin-1 (ET-1; 1 µM) was used as a positive control for the KBM cells.  In a similar 
fashion, time course experiments were performed using dacarbazine, etoposide, cisplatin, 
and melphalan, over the course of four hours. The fluorescence peak heights were 
compared to maximal Ca2+ response generated by 1 µM CPAF to derive % maximal 
values, to allow this assay to be semi-quantitative.  Maximal calcium release in KBP cells 
induced by lipid extracts derived from B16F10 melanoma cells treated with 
chemotherapeutic agents was observed around two hours of incubation of cells with 
chemotherapeutic agents (Figure 7C). Similar results were observed with the human 
melanoma cell line SK23MEL (Figure 7D).  
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Figure 7. Etoposide, cisplatin, and melphalan induce the generation of PAFR 
agonists.  
A and B. 5x106 B16F10 cells were treated with 100 µg/mL etoposide or DMSO 
vehicle for 1 hour. Cells were homogenized and lipids were extracted by organic 
separation. KBP (PAFR-expressing, A) or KBM (PAFR-null, B) cells were incubated 
with Fura-2 AM and treated with lipid extracts. Intracellular Ca2+ levels were 
monitored over time by measuring fluorescence. Excess CPAF or endothelin-1 (ET-1) 
(1 µM) was finally added to quantitate maximal Ca2+ response. C and D. 5x106 
B16F10 (C) or SK23MEL (D) cells treated with 100 µg/mL of chemotherapeutic 
agents or 0.5% DMSO vehicle for various time points. Lipid extracts from cell lysates 
were tested for PAFR agonistic activity using Fura-2-loaded KBP cells. Graphs show 
the mean ± SEM percentage of maximum intracellular calcium release induced by 1 
µM CPAF from at least four separate experiments. * denotes statistically significant (p 
< 0.05) changes in PAFR agonistic activity from control values for C and D. 
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 Melanoma cells from patients have been shown to express PAFR, which can 
contribute to metastasis [31].  However, previous studies revealed that murine B16F10 
melanoma cells do not express functional PAFRs as shown by lack of mRNA and failure 
to respond with an intracellular calcium mobilization response to CPAF [25].  To 
determine whether melanoma PAFR expression could modulate the generation of PAFR 
agonists by chemotherapy, the PAFR (Ptafr) gene (B16P) or MSCV2.1 retrovirus control 
vector (B16M) was previously transduced into B16F10 melanoma cells [25]. This way, 
PAFR expressing melanoma cells, B16P, induced greater amounts of PAFR agonists 
following treatment with dacarbazine, etoposide and cisplatin (Figure 8A). This finding 
suggests that PAFR expression on melanoma could contribute to the generation of PAFR 
agonists by chemotherapy. This is likely due to ox-GPCs acting on the melanoma cell 
PAFR to generate PAF enzymatically.  To determine whether the PAFR agonists 
generated from chemotherapy-treated cells was due to the oxidation of cell membrane 
lipids, cells were pretreated with or without antioxidants, vitamin C (Vit C) and N-
acetylcysteine (NAC), followed by treatment with chemotherapy or vehicle. Lipid 
extracts from B16P and B16M cells pretreated with antioxidants before treatment with 
cisplatin and etoposide were found to mobilize less calcium in KBP cells (Figure 8B). 
  
  47 
  
Figure 8. Generation of etoposide- and cisplatin-induced PAFR agonists is 
blocked by antioxidants and augmented by PAFR expression.  
A. PAFR-expressing B16F10 PAFR cells (B16P) or PAFR-null B16F10MSCV2.1 
(B16M) cells were treated with increasing doses of etoposide, dacarbazine, and 
cisplatin for 1 hour. Lipid extracts were isolated and then tested for the ability to 
activate the PAFR. The data are the mean ± SE percentage of maximum intracellular 
calcium response (normalized to CPAF) from three to four separate experiments. B. 
B16P and B16M cells were preincubated vitamin C (2.5 mM), NAC (5 mM), or 0.5% 
DMSO vehicle one hour prior to a one hour treatment with 100 µg/mL of etoposide or 
cisplatin. Lipid extracts were then isolated and tested for PAFR agonistic activity. The 
data are the mean ± SEM percentage of maximal intracellular calcium response 
(normalized to CPAF) from at least three separate experiments. * denotes statistically 
significant (p < 0.05) changes in PAFR agonistic activity from control values for A, 
and differences between chemotherapy-treated B16P and B16M cells in B. For C, the 
significant changes were for cisplatin at 10 µg/mL and for cisplatin, and etoposide at 
100 µg/mL versus 0 dose. 
PAF-R activation diminishes experimental
chemotherapy effectiveness via Tregs in a COX-2–
dependent process
Given our ﬁndings that intratumoral chemotherapy gener-
ates PAF-R agonists in vivo and that systemic PAF-R activation
augments experimental tumor growth via immunosuppres-
sion (30), we assessed whether intratumoral chemotherapy
could generate enough PAF-R agonists to modulate tumor
growth. Our protocol was modiﬁed in that WT and PAF-R–
deﬁcient (Ptafr!/!, PAFR-KO) mice underwent implantation
with B16F10 tumors on both dorsal hindquarters (2 tumors/
mouse). The left ﬂank tumors were treated with intratumoral
chemotherapy or PBS vehicle control starting at day 6 of tumor
cell implantation and repeated every 3 days until the termi-
nation of the experiment, whereas the other (right ﬂank)
tumors were left undisturbed. Intratumoral chemotherapy of
one tumor withmelphalan (15mg/kg) or etoposide (36mg/kg)
resulted in an enhanced growth of the second (undisturbed)
tumor in PAF-R–positive WT compared with Ptafr!/! hosts
(Fig. 4A–C). Though intratumoral chemotherapy resulted in
growth inhibition of the chemotherapy-treated left ﬂank
tumors, loss of host PAF-R function exerted no perceptible
effect on the left ﬂank tumor growth characteristics (Supple-
mentary Fig. S2). Subjectingmice to antioxidant treatment had
no effects on the untreated right ﬂank tumor growth by itself,
yet inhibited themelphalan-mediated augmentation of growth
Figure 1. Chemotherapy agents generate PAF-R agonist formation in melanoma cells. A, examples of PAF-R Ca2þ biochemical assays. PAF-R–expressing
KBP or PAF-R–negative KBM cells were loaded with Fura-2 AM and treated with lipid extracts derived from 5 # 106 B16F10 cells treated with 100 mg/mL
etoposide or DMSO vehicle for 1 hour, and intracellular Ca2þ levels monitored over time. Excess [1 mmol/L CPAF or endothelin-1 (ET-1)] was added at
the end of the assay to all w quantitatio of the C 2þ response. B, tim course of chemotherapy-g nerated PAF-R activity. Lipid extracts were
obtained from 5# 106 B16F10 cells treated with 100 mg/mL of chemotherapeutic agents or 0.5% DMSO vehicle for various times and tested for total PAF-R
agonistic activity using PAF-R–positive KBP cells loaded with the calcium-speciﬁc dye Fura-2. The data are the mean $ SE percentage of peak intracellular
calcium response as a percentage of that induced by 1 mmol/L CPAF from at least four separate experiments. C, dose responsiveness of chemotherapy-
generated PAF-R agonists in PAF-R–negative versus B16F10 cells expressing PAF-Rs. Lipid extracts were obtained from PAF-R–expressing B16F10PAF-R
(B16P) or control B16F10MSCV2.1 (B16M) cells treated with various doses of chemotherapeutic agents for 1 hour and tested for PAF-R agonistic
activity as above. Thedata are themean$SEpercentageof peak intracellular calcium response (normalized toCPAF) from three to four separate experiments.
D, chemotherapy agent-stimulated PAF-R agonist formation is inhibited by antioxidants. Lipid extracts were obtained from B16P and B16M cells
preincubated for 1 hour with antioxidants vitamin C (2.5 mmol/L), NAC (5 mmol/L), or 0.5% DMSO vehicle before a 1-hour treatment with 100 mg/mL
chemotherapeutic agents and tested for total PAF-R agonistic activity. The data are the mean $ SE percentage of peak intracellular calcium response
(normalized to CPAF) from at least three separate experiments. %, statistically signiﬁcant (P < 0.05) changes in levels of PAF-R agonist activity from control
values for B and C, and differences between chemotherapy-treated B16P an B16M cells in D. For C, the si niﬁcant changes were for cisplatin at
10 mg/mL and for cisplatin, and etoposide at 100 mg/mL versus 0 dose.
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 These results suggest that chemotherapeutics induce the formation of PAFR 
agonists in part via the oxidation of resident lipids in treated melanoma cells. Lastly, to 
quantitate (Figure 9) and determine the structural identity (Table 5) of the PAFR agonists 
in the lipid extracts, collaborator Robert Murphy used mass spectrometry with deuterated 
internal standards using previously published methodologies [26]. They found that 
etoposide treatment generated greater than two-fold levels of PAF (1-O-hexadecyl-2-
acetoyl-GPC), AzPAF (1-O-hexadecyl-2-azeleoyl-GPC), and BPAF (1-O-hexadecyl-2-
butanoyl-GPC), among others, compared to vehicle treated cells. The structures of these 
PAFR agonists are summarized in Table 5.  However, levels of the biologically inactive 
PAF precursor/metabolite lyso-PAF were unchanged following etoposide treatment. 
These in vitro studies demonstrate that chemotherapeutic agents, etoposide, cisplatin, and 
melphalan, induce melanoma cells to generate PAF and ox-GPCs with PAFR agonistic 
activity, in part due to ROS. 
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Figure 9. Structural characterization of etoposide-generated PAFR agonists. 
Lipid extracts from B16F10 cells treated with etoposide (100 µg/mL) or vehicle (0.5% 
DMSO) for 2 hours were collected. Lipid extracts were subjected to HPLC/MS/MS 
analysis. PAF and Ox-GPC species were quantified using deuterium-labeled internal 
standards. The data are expressed as mean ± SEM fold increase in PAFR agonist in 
etoposide over vehicle-treated. Representative of five separate experiments. * denotes 
statistically significant (p < 0.05) changes from vehicle-treated. Mass spectrometry 
analysis was kindly generated by Kathleen Harrison and Dr. Robert Murphy.  
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Table 5. Glycerophosphocholine species generated in response to etoposide 
treatment of B16F10 cells.  B16F10 cells were incubated for 2 hours with etoposide 
(100 µg/ml), or vehicle (0.5% DMSO) for 2 hours. PAF and Ox-GPC species from 
lipid extracts were quantified using deuterium-labeled internal standards. The table 
includes structures and amounts (pg per 106) of different GPCs in extracts from 
vehicle or etoposide-treated cells from 5 separate experiments. Mass spectrometry 
analysis was kindly generated by Kathleen Harrison and Dr. Robert Murphy.  
Glycerophosphocholine	 Vehicle-Treated		(pg/106	cells)	
Etoposide-Treated	
(pg/106	cells)	
PAF	 467	 949	
		 591	 982	
		 84	 321	
		 42	 188	
		 161	 301	
		 Mean	269	 Mean	548	
PAcPC	 1200	 3220	
		 2320	 3490	
		 5400	 12600	
		 380	 577	
		 520	 1453	
		 Mean	1964	 Mean	4268	
BPAF	 17.3	 35.3	
		 17.1	 39.4	
		 8.2	 26.8	
		 6.9	 19.5	
		 16	 31.2	
		 Mean	13.1	 Mean	30.4	
PBPC	 191	 441	
		 329	 467	
		 197	 335	
		 127	 379	
		 271	 751	
		 Mean	224	 Mean	475	
PPrPC	 3.8	 4.9	
		 8.4	 19.9	
		 0.1	 2.8	
		 3.2	 7.8	
		 8.4	 10.5	
		 Mean	4.8	 Mean	9.2	
PHPC	 1.4	 1.5	
		 3.8	 4.7	
		 1.3	 3.7	
		 7.2	 34.1	
		 11.3	 39.6	
		 Mean	5.0	 Mean	16.7	
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Glycerophosphocholine	 Vehicle-Treated		(pg/106	cells)	
Etoposide-Treated	
(pg/106	cells)	
AzPAF	 1.5	 22.5	
		 4.7	 15.3	
		 3.7	 42.3	
		 34.1	 41.5	
		 39.6	 44.8	
		 Mean	16.7	 Mean	33.3	
PAzPC	 219	 140	
		 97	 77	
		 139	 179	
		 362	 336	
		 251	 497	
		 Mean	214	 Mean	246	
OVPAF	 1.5	 6.9	
		 1.6	 3.5	
		 1.2	 1.2	
		 1.3	 0.69	
		 0.56	 0.8	
		 Mean	1.2	 Mean	2.6	
ONPAF	 1.9	 8.8	
		 1.3	 4	
		 1.3	 5.9	
		 0.18	 0.29	
		 0.75	 0.25	
		 Mean	1.1	 Mean	3.8	
POVPC	 3.4	 7.2	
		 1.5	 6	
		 6.5	 8.6	
		 4.2	 4.2	
		 4.3	 5.7	
		 Mean	4.0	 Mean	6.3	
PONPC	 23.1	 56.4	
		 16.8	 35.2	
		 23.8	 47.4	
		 8.2	 9.4	
		 6.7	 11.3	
		 Mean	15.7	 Mean	31.9	
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Table 5. Glycerophosphocholine species generated in response to etoposide 
treatment of B16F10 cells.  B16F10 cells were incubated for 2 hours with etoposide 
(100 µg/ml), or vehicle (0.5% DMSO) for 2 hours. PAF and Ox-GPC species from 
lipid extracts were quantified using deuterium-labeled internal standards. The table 
includes structures and amounts (pg per 106) of different GPCs in extracts from 
vehicle or etoposide-treated cells from 5 separate experiments. Mass spectrometry 
analysis was kindly generated by Kathleen Harrison and Dr. Robert Murphy.  
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B. Melanoma tumors treated with intratumoral chemotherapy produce 
immunosuppressive PAFR agonists 
 While systemic intravenous administration of chemotherapy is the most common 
route of administration, other routes of administration are useful in providing localized 
high-dose chemotherapy. IPL and intratumoral injections are available recourses to avoid 
the damaging effects of systemic high-dose chemotherapy on vital organs [99, 113, 114, 
138, 139]. In order to ascertain whether chemotherapy generates PAFR agonists in vivo, 
an intratumoral injection approach was used to isolate the effects of drug on the tumor 
rather than the host. First, lipids were extracted from B16F10 tumors in mice one hour 
after intratumoral injection with either etoposide, melphalan, or vehicle. Lipid extracts 
from chemotherapy-treated tumors induced greater than a 10-fold increase in maximal 
calcium mobilization in KBP cells, compared to vehicle treated tumors (Figure 10A). 
Similar results were seen with human melanoma SK23MEL tumors transplanted into 
SCID mice (Figure 10B). Additionally, when the mice were put on an antioxidant diet 
(Vit C + NAC) before tumor implantation and chemotherapy (etoposide or melphalan) 
injection, the PAFR agonistic potential of the lipid extracts was diminished (Figure 10A). 
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Figure 10. Intratumoral etoposide, and melphalan induces the generation of 
PAFR agonists.  
A. WT mice were fed regular chow, or vitamin C-enriched chow (10 mg/kg) and NAC 
(5 mM) in water, ad libitum for 10 days before implantation of B16F10 tumors. B. 
SK23MEL tumors were implanted on SCID mice on a regular diet. A and B. Lipid 
extracts were obtained from 10 mg samples of tumors 1 hour following intratumoral 
injection with either etoposide (36 mg/kg), or melphalan (15 mg/kg), or PBS vehicle 
(100 µL). Lipid extracts were then tested by calcium mobilization for PAFR agonistic 
activity. The data are the mean ± SEM percentage of maximum intracellular calcium 
response (normalized to CPAF) from four to six separate tumors. * denotes statistically 
significant (p < 0.05) changes in levels of PAFR agonists in comparison to vehicle-
treated tumors.  
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 Since the generation of PAFR agonists was found in tumors following etoposide 
and melphalan chemotherapy injection, this observation led to the hypothesis that PAFR 
agonists could promote growth of a second tumor via systemic immunosuppression. 
Systemic administration of chemotherapeutics was found to be effective in reducing 
B16F10 tumor growth, but highly toxic to mice. Thus, to minimize toxicity in the mice  
and potential effects of chemotherapeutic agents on the immune system, a dual-tumor 
model was devised in which one tumor is treated with high-dose chemotherapy, while the 
contralateral tumor is measured over time. This dual-tumor model is not only a relevant 
model for intratumoral and IPL therapy in the clinic, but perhaps also a model of 
metastatic tumor growth. Using this model melphalan was found to have reduced efficacy 
in reducing growth of a second tumor in WT hosts compared to PAFR KO mice (Figure 
11A). Notably, there was no discernable difference in growth of a second tumor between 
WT and PAFR KO mice when tumors were treated with vehicle (Figure 11B). This 
finding suggests that this difference in tumor growth may be PAFR-dependent.   
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Fig	Supplementary	S3	
is cannulated and blood along with melphalan is perfused for
30 to 60 minutes in the heated (40!C) limb (39). Minimal
amounts of PAF-R agonists were found in the circulating
perfusate before addition of the melphalan (Fig. 6A). However,
once the melphalan chemotherapy began perfusing in the
heated limb, signiﬁcant amounts of PAF-R agonistic activity
were measured in the perfusates, with the highest amounts
found at the conclusion of regional chemotherapy treatment.
Structural characterization of perfusates using mass spec-
trometry identiﬁed PAF and several Ox-GPC species
(Fig. 6B). These studies indicate that chemotherapy exposure
generates systemic PAF-R agonists in humans.
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Figure 4. Intratumoral chemotherapy treatment augments the growth of untreated B16F10 melanomas in a PAF-R–dependent manner. WT and PAFR-KO
(Ptafr"/") mice were implanted with B16F10 tumors on both the dorsal hind ﬂanks. A–C, six days later (and every 3 days afterward), one of the tumors (on
the left side) was treated with 15 mg/kg melphalan (n¼ 6–7; A and B, 36 mg/kg etoposide (n¼ 9–12; C), or vehicle (n¼ 5–6), and the other tumor (on the right
side) left undisturbed. The data depicted are the mean $ SE of tumor volume of untreated tumors over time. B, data represent the volume of untreated
tumors at day 17 from vehicle and melphalan-treated WT and PAFR-KO mice. D, effect of antioxidants on the melphalan-mediated increased tumor
growth. WT mice were placed on antioxidant diet as in Fig. 3 for 10 days before placement of dual B16F10 tumors, followed by intratumoral treatment with
melphalan (n ¼ 10–11) every 3 days starting at day 6. The data depicted are the mean $ SE of tumor volume of untreated tumors over time. Between
WT and PAFR-KO mice, there were no statistically signiﬁcant differences in the growth of chemotherapy- or vehicle-injected tumors nor the growth of
the undisturbed tumors in response to vehicle treatment of the contralateral tumors. Statistical signiﬁcance of changes in tumor volumes denoted by
%%, P < 0.01; %, P < 0.05; #, P < 0.1.
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Figure 11. Intratumoral melphalan treatment augments the growth of untreated 
6F10 mela omas in a PAFR–dependent manner.  
B16F10 tumors were implanted on bilateral dorsal hind flanks in WT and PAFR-KO 
(Ptafr-/-) mice. A-D. Six days after implantation and every third day thereafter, the left 
tumor was injected with melphalan (15 mg/kg; n = 6-7; A and B), or vehicle (n = 5-6), 
while the contralateral tumor was undisturbed and measured. The data depicted are the 
me n ± SEM of tumor volume of untreated tumors over time. B. Data depicted is the 
tumor volume on day 17 from WT and PAFR-KO mice treated with intratumoral 
vehicle or melphalan. C and D. As in Fig. 8 mice were fed an antioxidant diet for 10 
days before implantation of bilateral B16F10 tumors. Six days after implantation, one 
tumor from each mouse was injected with melphalan (n = 10–11) and every 3 days 
thereafter. Th  data depicted are the mean ± SEM of tumor volume of untreated 
tumors over time. D. Data represent the volume of untreated tumors at day 16 from 
melphalan-treated WT and PAFR-KO mice with regular or antioxidant diet. Statistical 
significance of changes in tumor volumes denoted by ** (p < 0.01); * (p < 0.05); # (p 
< 0.1).  
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Figure 4. Intratumoral chemotherapy treatment augments the growth of untreated B16F10 melanomas in a PAF-R–dependent manner. WT and PAFR-KO
(Ptafr"/") mice were implanted with B16F10 tumors on both the dorsal hind ﬂanks. A–C, six days later (and every 3 days afterward), one of the tumors (on
the left side) was treated with 15 mg/kg melphalan (n¼ 6–7; A and B, 36 mg/kg etoposide (n¼ 9–12; C), or vehicle (n¼ 5–6), and the other tumor (on the right
side) left undisturbed. The data depicted are the mean $ SE of tumor volume of untreated tumors over time. B, data represent the volume of untreated
tumors at day 17 from vehicle and melphalan-treated WT and PAFR-KO mice. D, effect of antioxidants on the melphalan-mediated increased tumor
growth. WT mice were placed on antioxidant diet as in Fig. 3 for 10 days before placement of dual B16F10 tumors, followed by intratumoral treatment with
melphalan (n ¼ 10–11) every 3 days starting at day 6. The data depicted are the mean $ SE of tumor volume of untreated tumors over time. Between
WT and PAFR-KO mice, there were no statistically signiﬁcant differences in the growth of chemotherapy- or vehicle-injected tumors nor the growth of
the undisturbed tumors in response to vehicle treatment of the contralateral tumors. Statistical signiﬁcance of changes in tumor volumes denoted by
%%, P < 0.01; %, P < 0.05; #, P < 0.1.
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Figure 4. Intratumoral chemotherapy treatment augments the growth of untreat d B16F10 melanomas in a PAF-R–dependent manner. WT and PAFR-KO
(Ptafr"/") mice were implanted with B16F10 tumors on both the dorsal hind ﬂanks. A–C, six days later (and every 3 days afterward), one of the tumors (on
the left side) was treated with 15 mg/kg melphalan (n¼ 6–7; A and B, 36 mg/kg etoposide (n¼ 9–12; C), or vehicle (n¼ 5–6), and the other tumor (on the right
side) left un isturbed. The ata depicted are the mean $ SE umor volume of untreated tumors over time. B, data represent the volume of untreated
tumors at day 7 from vehicle and melphalan-treated WT and PAFR-KO mice. D, effect of antioxidants on the melphalan-mediated increased tumor
growth. WT mice were placed on antioxidant diet as in Fig. 3 for 10 days before placement of dual B16F10 tumors, followed by intratumoral treatment with
melphalan (n ¼ 10–11) every 3 days star ing at day 6. The data depicted are the mean $ SE of tumor volume of untreated tumors over time. Betw en
WT and PAFR-KO m ce, ther were no statistically signiﬁc nt differ nces in t e growth of chemother py- or vehicle-injected tumors nor the growth of
the undisturbed tumors in response to vehicle treatment of the contralateral tumors. Statistical signiﬁcance of changes in tumor volumes denoted by
%%, P < 0.01; %, P < 0.05; #, P < 0.1.
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 In light of evidence suggesting that chemotherapy generated PAFR agonists via 
the oxidation of lipids in vivo, this evidence led to the hypothesis that ox-GPCs might 
also be responsible for the increased growth of a second tumor in WT mice. To test this 
hypothesis, mice were kept on an antioxidant diet (vitamin C + NAC) for 10 days before 
the implantation of tumors. Using a dual-tumor model, it was found that when one tumor 
was treated with melphalan, contralateral tumor growth in mice on antioxidants had 
significantly decreased tumor growth compared with those on a normal diet (Figure 11C 
and 11D). Similar, results were observed when tumors were treated with etoposide 
(Figure 12A and B). Notably, there was no difference in contralateral tumor growth from 
chemotherapy (melphalan or etoposide) treated tumors between PAFR KO mice given 
antioxidants and normal diet (Figure 13). These findings suggest that the promotion of 
growth of a second tumor was mediated by PAFR agonists produced by ROS in tumors 
treated with chemotherapy. 
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Figure 12. Intratumoral etoposide augments untreated tumor growth in a PAFR 
and ROS-dependent manner.  
A. B16F10 tumors were implanted on bilateral dorsal hind flanks in WT and PAFR-
KO (Ptafr-/-) mice. A and B. Six days after implantation and every third day 
thereafter, the left tumor was injected with etoposide (36 mg/kg; n = 5-6; A and B), or 
vehicle (n = 5-6), while the contralateral tumor was undisturbed and measured. The 
data depicted are the mean ± SEM of tumor volume of untreated tumors over time. B. 
Data represent the volume of untreated tumors at day 16 from etoposide-treated WT 
and PAFR-KO mice (n=9-12) with regular or antioxidant diet. Statistical significance 
of changes in tumor volumes denoted by ** (p < 0.01); * (p < 0.05); # (p < 0.1).  
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B 
is cannulated and blood along with melphalan is perfused for
30 to 60 minutes in the heated (40!C) limb (39). Minimal
amounts of PAF-R agonists were found in the circulating
perfusate before addition of the melphalan (Fig. 6A). However,
once the melphalan chemotherapy began perfusing in the
heated limb, signiﬁcant amounts of PAF-R agonistic activity
were measured in the perfusates, with the highest amounts
found at the conclusion of regional chemotherapy tr atment.
Structural characterization of perfusates using mass spec-
trometry identiﬁed PAF and several Ox-GPC species
(Fig. 6B). These studies indicate that chemotherapy exposure
generates systemic PAF-R agonists in humans.
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Figure 4. Intratumoral chemotherapy treatment augments the growth of untreated B16F10 melanomas in a PAF-R–dependent manner. WT and PAFR-KO
(Ptafr"/") mice were implanted with B16F10 tumors on both the dorsal hind ﬂanks. A–C, six days later (and every 3 days aft rward), one of the tumors (on
the left side) was treated with 15 mg/kg melphalan (n¼ 6–7; A and B, 36 mg/kg etoposide (n¼ 9–12; C), or vehicle (n¼ 5–6), and the other tumor (on the right
side) left undisturbed. The data depicted are the mean $ SE of tumor volume of untreated tumors over time. B, data represent the volume of untreated
tumors at day 17 from vehicle and melphalan-treated WT and PAFR-KO mice. D, effect of antioxidants on the melphalan-mediated increased tumor
growth. WT mice were placed on antioxidant diet as in Fig. 3 for 10 days befo e placement of dual B16F10 tumors, followed by intratumoral treatment with
melphalan (n ¼ 10–11) every 3 days starting at day 6. The data depicted are the mean $ SE of tumor volume of untreated tumors over time. Between
WT and PAFR-KO mice, there were no statistically signiﬁcant differences in the growth of chemotherapy- or vehicle-injected tumors nor the growth of
the undisturbed tumors in response to vehicle treatment of the contralateral tumors. Statistical signiﬁcance of changes in tumor volumes denoted by
%%, P < 0.01; %, P < 0.05; #, P < 0.1.
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Figure 13. Growth of tumors treated with intratumoral melphalan or etoposide 
versus vehicle at Day 17. 
As in Fig. 9 mice were fed an antioxidant diet for 10 days. B16F10 tumors were then 
implanted on bilateral dorsal hind flanks in WT and PAFR-KO (Ptafr-/-) mice. Six 
days after implantation, the left tumor from each mouse was injected with vehicle, 
melphalan (15 mg/kg; n = 9–11) or etoposide (36 mg/kg; n=9-12), and every 3 days 
thereafter. The data depicted are the mean tumor volumes ± SEM at Day 17 post-
tumor implantation of tumors treated with chemotherapy, or vehicle, implanted on the 
left flank. Between WT & PAFR-KO mice, there were no statistically significant 
differences in the growth of chemotherapy- or vehicle-injected tumors. 
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Figure	S2.		LeC	ﬂank	tumor	growth:	eﬀect	of	chemotherapy	and	
an:oxidants	on	the	growth	of	treated	tumors.		WT	&	PAFR-KO	
(Ptafr-/-)	mice	were	placed	on	regular	(NL)	or	anJoxidant	diet	as	in	
Fig.	3	for	10	days	before	implantaJon	of	dual	B16F10	tumors,	
followed	by	intratumoral	treatment	with	A)	36	mg/kg	etoposide	
(n=9-12),	or	B)	15	mg/kg	melphalan	(n=9-11),	or	vehicle	(n=7-10)	
every	3	days	starJng	at	day	6.		The	data	depicted	are	the	mean	tumor	
volumes	±	SE	at	Day	17	post-tumor	implantaJon	of	tumors	treated	
with	chemotherapy,	or	vehicle,	implanted	on	the	le_	ﬂank.		Between	
WT	&	PAFR-KO	mice,	there	were	no	staJsJcally	signiﬁcant	
diﬀerences	in	the	growth	of	chemotherapy-	or	vehicle-injected	
tumors.		Moreover,	there	were	no	diﬀerences	in	the	growth	of	the	
le_	ﬂank	tumors	in	response	to	vehicle	treatment	of	the	contralateral	
tumors.			
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 There are significant data suggesting that COX-2 is involved in the 
immunosuppressive effects of UVB and PAF [16, 24, 25, 118, 130, 131]. Thus, this 
evidence led to the hypothesis that COX-2 was involved in mediating the increase in 
contralateral tumor growth by chemotherapy in a PAFR-dependent fashion. Similarly, it 
was hypothesized that CPAF administration could modulate tumor growth in a COX-2 
dependent fashion. To test this hypothesis mice were treated with either intraperitoneal 
injections of vehicle or CPAF, and vehicle or COX-2 inhibitor SC-236, every 6 days after 
single tumor implantation on Day 0. By measuring tumors over time, it was found that 
CPAF i.p. promoted tumor growth (Figure 14A). While SC-236 did not modulate tumor 
growth alone, it did inhibit the tumor promoting effects of CPAF. Similar results were 
seen in using a structurally different COX-2 inhibitor, NS398 (Figure 14B). Noteworthy, 
however, is the fact that neither SC-236, nor CPAF, had any effect on tumor growth in 
PAFR KO mice (Figure 14C). Next to test the hypothesis that COX-2 inhibitors could 
block the tumor promoting effects of chemotherapy, a dual-tumor model was used, where 
mice were either treated with COX-2 inhibitor, SC-236, or vehicle every three days 
during intratumoral chemotherapy treatment. Tumor measurements over time showed 
that in mice treated with intratumoral chemotherapy, untreated tumors grew smaller and 
at a slower rate when mice were treated with COX-2 inhibitor SC-236 compared to mice 
given vehicle treatment (Figure 15A and 15B). These findings indicate that COX-2 
inhibitors can block the growth promoting effect of chemotherapy on a contralateral 
tumor.  
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Discussion
Chemotherapy is the most commonly used medical treat-
ment for cancer. The present study describes a previously
unappreciated mechanism by which chemotherapy exposure
results in the production of PAF-R agonists, which are known
to inhibit tumor immunity (30). These data support the model
that Ox-GPC PAF-R agonists produced in part due to ROS from
chemotherapeutic agents can exert systemic immunosuppres-
sive effects. That chemotherapeutic agent-triggered PAF-R
agonist formation and augmentation of tumor growth are
partially inhibited by antioxidants suggests that antioxidants
could have potential use in chemotherapy protocols. Of inter-
est, systemic antioxidants have been championed for adjuvant
use along with chemotherapy to decrease therapy side effects
(40, 41). Yet, use of antioxidants along with chemotherapy is
considered controversial due to concerns about possible inter-
ference with chemotherapeutic agent-mediated direct killing
of tumor cells (42, 43). It should be noted that the present
studies indicate that antioxidant treatment alone or in
chemotherapy-treated PAF-R–deﬁcient mice did not have any
perceptible effects on tumor growth.
Oxidation of esteriﬁed fatty acyl residues introduces oxy
functions, rearranges bonds and fragments carbon-carbon
bonds by b-scission that generate a myriad of phospholipid
reaction products including PAF-R agonists (19–25). In con-
trast to the tightly controlled enzymatic pathways for PAF
biosynthesis, large amounts of numerous Ox-GPC PAF-R ago-
nists can be produced nonenzymatically. The present studies
not only demonstrate that chemotherapy-generated PAF-R
agonistic activity is diminished by antioxidants, but structural
characterization of this activity reveals Ox-GPCs known to be
produced nonenzymatically. Consistent with the notion that
chemotherapy is a potent pro-oxidative stressor, intratumoral
injection of melphalan resulted in increased urine levels of
immunoreactive 8-isoprostane (8-iso Prostaglandin F2a), an
eicosanoid formed from free radical-catalyzed peroxidation of
arachidonate, which was blunted in mice fed antioxidant diet
(data not shown). It is likely that tumor cellular membranes
3 6 9 12 15 16 17 18
0
1,000
2,000
3,000
 Vehicle
CPAF
COX-2 inhibitor (SC-236)
SC-236 + CPAF
Tu
m
or
 v
ol
um
e 
(m
m3
)
Tu
m
or
 v
ol
um
e 
(m
m3
)
Tu
m
or
 v
ol
um
e 
(m
m3
)
Tu
m
or
 v
ol
um
e 
(m
m3
)
Days Days
DaysDays
*
D
A B
C
Single tumor model Single tumor model
Dual tumor model Dual tumor model
Figure 5. Role of COX-2 and Tregs in chemotherapy-mediated PAF-R–dependent augmentation of tumor growth. A and B, COX-2 inhibitor blocks PAF-R
augmentation of tumor growth. WT mice (n ¼ 6–7) implanted with a single tumor were treated at day 0 and every 6 days with intraperitoneal injections
of CPAF (250 ng) or vehicle, with or without COX-2 inhibitors SC-236 (200 ng; A), NS-398 (5 mg; B). C, COX-2 inhibitor blocks chemotherapy-mediated
augmentation of tumor growth.WTmice implantedwith two tumorswere treatedwith SC-236or vehicle at day0 andevery 3days, andunderwent intratumoral
treatment with PBS vehicle (n ¼ 7) or melphalan (n ¼ 16; C) every 3 days, starting at day 6. Tumor growth was assessed over time as in Fig. 4. The
data depicted are the mean " SE of tumor volume of untreated tumors over time in which the contralateral tumor was treated with chemotherapeutic
agent. D, depleting Treg blocks etoposide-mediated enhanced growth of secondary tumors. WT mice (n ¼ 7–8) were treated with isotype control (IgG1 and
IgM1) or depleting antibodies against CD25 (clones PC61.5.3 IgG1 and 7D4 IgM1, 1 mg each) two days before dual tumor implantation and etoposide
treatment as outlined in Fig. 4. Statistical signiﬁcance of changes in tumor volumes is denoted: ##, P < 0.01; #, P < 0.05; #, P < 0.1.
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ment for cancer. Th pres nt study describ s a previously
unappreciated mechanism by which c emot rapy xposure
results in the producti n of PAF-R agonists, which are known
to inhibit tumor immunity (30). These data support the mod l
that Ox-GPC PAF-R agonists produced in part due to ROS from
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use along with chemot erapy to decrease therapy side effects
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considered controversial due to concerns about possible inter-
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of tumor cells (42, 43). It should be noted that the present
studies indicate that antioxidant treatment alone or in
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perceptible effects on tumor growth.
Oxidation of esteriﬁed fatty acyl residues introduces oxy
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Figur  14. COX-2 inhibitors block PAFR-mediated augmentation in tumor 
growth. 
A and B. A si gle B16F10 t or was implant d on the orsal hind flanks in WT mice 
(n = 6-7). tarting n the day of tum r i plantation, the mice were treated every 6 
days with CPAF (250 ng i.p.) or vehicle, and vehicle or COX-2 inhibitors SC-236 (200 
g i.p.; A), NS-398 (5 µg i.p.; B). C. A singl  B16F1  tumor was implanted on the 
dorsal hind flanks in PAFR-KO mice (n = 4-5). Mice were treated at tumor 
implantation and every 3 days with intraperitoneal injections of v hi l , CPAF (250 
ng), or COX-2 inhibitor SC-236 (200 ng). Tumor growth was measured over time. The 
data depicted are the mean ± SEM of tumor volume. Statistical significance of changes 
in tumor volumes is denoted: ** (p < 0.01); * (p < 0.05); # (p < 0.1). 
  
Fig	Supplementary	S4	
Figure	S4.		CPAF	and	COX-2	inhibitor	have	no	 ﬀect	on	B16F10	tumor	growth	i 	PAF-R-	
deﬁ ient	 ice.		PAFR-KO	(Ptafr-/-)	mice	implant d	with	a	single	tumor	were	tr ated	at		
day	0	and	every	3	days	with	ip	injecJons	of	CP F	(250	ng)	or	vehicle	or	 -2	inhibitor		
SC-236	(200	ng).		Tumor	growth	 as	assessed	over	Jme	as	in	Fig	4.		The	data	depicted		
are	the	mean	±	SE	of	tumor	volume	over	Jme	in	4-5	mice	per	experimental	group.				
	
C 
  61 
  
Figure 15. COX-2 inhibitors block melphalan- and etoposide-induced 
augmentation of tumor growth. 
A and B. B16F10 tumors were implanted on bilateral dorsal hind flanks in WT mice. 
Mice were treated with COX-2 inhibitor SC-236 (200 ng i.p.) or vehicle every 3 days 
starting on the day of tumor implantation. Left tumors were also injected on day 6 
post-tumor implantation with PBS vehicle (n = 7) or chemotherapy (melphalan (n = 
16; A) or etoposide (n=12-14; B) and every 3 days thereafter . Untreated tumors were 
measured over time as in Fig. 11. The data depicted are the mean ± SEM of tumor 
volume of untreated tumors over time in which the contralateral tumor was treated 
with chemotherapeutic agent. Statistical significance of changes in tumor volumes is 
denoted: ** (p < 0.01); * (p < 0.05); # (p < 0.1). 
C 
Fig	Supplementary	S5	
Figure	S5.		COX-2	inhibitor	blocks	etoposi e-mediated	augmenta:on	of	tumor	growth.			
WT	mice	implanted	with	two	tumors	were	treated	with	SC-236	(200	ng)	or	vehicle	at	day	0		
and	every	3	days,	and	underwent	intratumoral	treatment	with	PBS	vehicle	(n=11-13)	or		
36mg/kg	etoposide	(n=12-14)	every	3	days	starJng	at	day	6.		Tumor	growth	was	assessed		
over	Jme	as	in	Fig	4.		The	data	depicted	are	the	mean	±	SE	of	tumor	volume	of	untreated		
tumors	over	Jme	in	which	the	contralateral	tumor	was	treated	with	etoposide.			
StaJsJcally	signiﬁcant	diﬀerences	were	noted	in	tumor	volumes	(*	P<0.05	and	#	P<0.1).						
	
Discussion
Chemotherapy is the most commonly used medical treat-
ment for cancer. The present study describes a previously
unappreciated mechanism by which chemotherapy exposure
results in the production of PAF-R agonists, which are known
to inhibit tumor immunity (30). These data support the model
that Ox-GPC PAF-R agonists produced in part due to ROS from
chemotherapeutic agents can exert systemic immunosuppres-
sive effects. That chemotherapeutic agent-triggered PAF-R
agonist formation and augmentation of tumor growth are
partially inhibited by antioxidants suggests that antioxidants
could have potential use in chemotherapy protocols. Of inter-
est, systemic antioxidants have been championed for adjuvant
use along with chemotherapy to decrease therapy side effects
(40, 41). Yet, use of antioxidants along with chemotherapy is
considered controversial due to concerns about possible inter-
ference with chemotherapeutic agent-mediated direct killing
of tumor cells (42, 43). It should be noted that the present
studies indicate that antioxidant treatment alone or in
chemotherapy-treated PAF-R–deﬁcient mice did not have any
perceptible effects on tumor growth.
Oxidation of esteriﬁed fatty acyl residues introduces oxy
functions, rearranges bonds and fragments carbon-carbon
bonds by b-scission that generate a myriad of phospholipid
reaction products including PAF-R agonists (19–25). In con-
trast to the tightly controlled enzymatic pathways for PAF
biosynthesis, large amounts of numerous Ox-GPC PAF-R ago-
nists can be produced nonenzymatically. The present studies
not only demonstrate that chemotherapy-generated PAF-R
agonistic activity is diminished by antioxidants, but structural
characterization of this activity reveals Ox-GPCs known to be
produced nonenzymatically. Consistent with the notion that
chemotherapy is a potent pro-oxidative stressor, intratumoral
injection of melphalan resulted in increased urine levels of
immunoreactive 8-isoprostane (8-iso Prostaglandin F2a), an
eicosanoid formed from free radical-catalyzed peroxidation of
arachidonate, which was blunted in mice fed antioxidant diet
(data not shown). It is likely that tumor cellular membranes
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Figure 5. Role of COX-2 and Tr gs in chemotherapy-mediated PAF-R–dependent augmentation of tumor growth. A and B, COX-2 inhibitor blocks PAF-R
augmentation of tumor growth. WT mice (n ¼ 6–7) implanted with a single tumor were treated at day 0 and every 6 days with intraperitoneal injections
of CPAF (250 ng) or vehicle, with or without COX-2 inhibitors SC-236 (200 ng; A), NS-398 (5 mg; B). C, COX-2 in ibitor blocks ch mother py-mediated
augmentation of tumor growth.WTmice implantedwith two tumorswere treatedwith SC-236or vehicle at day0 andevery 3days, andunderwent intratumoral
treatment with PBS vehicle (n ¼ 7) or melphalan (n ¼ 16; C) every 3 days, starting at day 6. Tumor growth was assessed over time as in Fig. 4. The
data depicted are the mean " SE of tumor volume f untreated tumors over time in which the c ntralateral tumor w s treated with chemotherapeutic
agent. D, depleting Treg blocks etoposide-mediated enhanced growth of se ondary tumors. WT mice ( ¼ 7–8) were treated with isotype control (IgG1 and
IgM1) or depleting antibodies against CD25 (clones PC61.5.3 IgG1 and 7D4 IgM1, 1 mg each) two days before dual tumor implantation and etoposide
treatment as outlined in Fig. 4. Statistical signiﬁcance of changes in tumor volumes is denoted: ##, P < 0.01; #, P < 0.05; #, P < 0.1.
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 There are several reports suggesting that Tregs are involved in the 
immunosuppressive effect of UVB and PAF [24, 25, 118, 119]. This information led to 
the hypothesis that Tregs could mediate the immunosuppressive effects of chemotherapy. 
To test this hypothesis, an α-CD25 depleting antibody was used to deplete Tregs [24, 25]. 
In a dual tumor model, it was found that depleting Tregs using an antibody approach 
protected against growth of the untreated tumor, when treating the contralateral tumor 
with etoposide (Figure 16D). These data support the hypothesis that Tregs might be 
involved in mediating the promotion of tumor growth by CPAF. To investigate whether 
generated PAFR agonists might induce the expansion of FOXP3+ Tregs, a FOXP3-EGFP 
reporter mouse was obtained from JAX [133]. Using flow cytometry, mice treated with 
CPAF were found to have increased populations of intratumoral Tregs nine days after 
CPAF injection in a process blocked by COX-2 inhibitors (Figure 16A and B). This 
increase in Treg numbers in tumors and draining LNs, however, could be attenuated by 
COX-2 inhibitor, SC-236, as measured by EGFP (Egfp) expression by qRT-PCR (Figure 
16C). 
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Fig	Supplementary	S6	
Figure	S6.	Eﬀect	of	COX-2	inhibitor	on	tumoral	Treg	levels.		A	group	of	FoxP3EGFP	WT	mice	(n=6-9)		
were	implanted	with	a	single	B16F10	tumor	followed	by	treatment	either	with	COX-2	inhibitor		
(SC-236,	200ng)	or	vehicle	(PBS,	100µl)	i.p.	starJng	at	day	0	and	repeated	every	3	days	unJl	day	15.			
CPAF/vehicle	treatments	were	given	at	day	0,	6	and	12.		Mice	were	sacriﬁced	at	days		
6,	9,	12,	15	and	18	and	tumors	harvested	and	processed	for	the	analysis	of	EGFP	posiJve	cells		
as	a	surrogate	marker	for	Tregs	by	ﬂow	cytometry	and	qPCR	studies.	A)	Data	(ﬂow	cytometry)		
are	the	Mean	±	SE	of	EGFP+	cells	(normalized	to	vehicle	control	mice)	in	CPAF	and		
SC-236	+	CPAF	groups	in	tumors	over	the	period	of	Jme.		B)	A	representaJve	ﬂow	analysis	for		
tumoral	EGFP+	cells	at	day	9	in	CPAF	and	SC-236	+	CPAF	groups	are	shown.		
C)	qPCR	analysis	for	the	EGFP	mRNA	normalized	to	CD3e	in	the	CPAF	and	SC-236	+	CPAF	groups		
are	shown.		*	Denotes	staJsJcally	signiﬁcant	diﬀerence	(P<0.05)	between	CPAF	versus		
SC-236	+	CPAF	groups.			
	
Discussion
Chemotherapy is the most commonly used medical treat-
ment for cancer. The present study describes a previously
unappreciated mechanism by which chemotherapy exposure
results in the production of PAF-R agonists, which are known
to inhibit tumor immunity (30). These data support the model
that Ox-GPC PAF-R agonists produced in part due to ROS from
chemotherapeutic agents can exert systemic immunosuppres-
sive effects. That chemotherapeutic agent-triggered PAF-R
agonist formation and augmentation of tumor growth are
partially inhibited by antioxidants suggests that antioxidants
could have potential use in chemotherapy protocols. Of inter-
est, systemic antioxidants have been championed for adjuvant
use along with chemotherapy to decrease therapy side effects
(40, 41). Yet, use of antioxidants along with chemotherapy is
considered controversial due to concerns about possible inter-
ference with chemotherapeutic agent-mediated direct killing
of tumor cells (42, 43). It should be noted that the present
studies indicate that antioxidant treatment alone or in
hemotherapy-treated PAF-R–d ﬁcie t mice did not have any
perceptible effects on tumor growth.
Oxidation of esteriﬁed fatty acyl residues introduces oxy
functions, rearranges bonds and fragments carbon-carbon
bonds by b-scission that generate a myriad of phospholipid
reaction products including PAF-R agonists (19–25). In con-
trast to the tightly controlled enzymatic pathways for PAF
biosynthesis, large amounts of numerous Ox-GPC PAF-R ago-
nists can be produced nonenzymatically. The present studies
not only demonstrate that chemotherapy-generated PAF-R
agonistic activity is diminished by antioxidants, but structural
characterization of this activity reveals Ox-GPCs known to be
produced nonenzymatically. Consistent with the notion that
chemotherapy is a potent pro-oxidative stressor, intratumoral
injection of melphalan resulted in increased urine levels of
immunoreactive 8-isoprostane (8-iso Prostaglandin F2a), an
eicosanoid formed from free radical-catalyzed peroxidation of
arachidonate, which was blunted in mice fed antioxidant diet
(data not shown). It is likely that tumor cellular membranes
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Figure 5. Role of COX-2 and Tregs in chemotherapy-mediated PAF-R–dependent augmentation of tumor growth. A and B, COX-2 inhibitor blocks PAF-R
augmentation of tumor growth. WT mice (n ¼ 6–7) i pl nted with a single tumor were treated at day 0 and every 6 days with intraperitoneal injections
of CPAF (250 ng) or vehicle, with or without COX-2 inhibitors SC-236 (200 ng; A), NS-398 (5 mg; B). C, COX-2 inhibitor blocks chemotherapy-mediated
augmentation of tumor growth.WTmice implantedwith two tumorswere treatedwith SC-236or vehicle t day0 andevery 3days, andunderwe t intratumoral
treatment with PBS vehicle (n ¼ 7) or melphalan (n ¼ 16; C) every 3 days, starting at day 6. Tumor growth was assessed over time as in Fig. 4. The
data depicted are the mean " SE of tumor volume of untreated tumors over time in which the contralateral tumor was treated with chemotherapeutic
agent. D, depleting Treg blocks etoposide-mediated enhanced growth of secondary tumors. WT mice (n ¼ 7–8) were treated with isotype control (IgG1 and
IgM1) or depleting antibodies against CD25 (clones PC61.5.3 IgG1 and 7D4 IgM1, 1 mg each) two days before dual tumor implantation and etoposide
treatment as outlined in Fig. 4. Statistical signiﬁcance of changes in tumor volumes is denoted: ##, P < 0.01; #, P < 0.05; #, P < 0.1.
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Figure	S6.	Eﬀect	of	COX-2	inhibitor	on	tumoral	Treg	levels.		A	group	of	FoxP3EGFP	WT	mice	(n=6-9)		
were	implanted	with	a	single	B16F10	tumor	followed	by	treatment either	with	COX-2	inhibitor		
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CPAF/vehicle	treatments	were	given	at	day	0,	6	and	12.		Mice	were	sacriﬁced	at	days		
6,	9,	12,	15	and	18	and	tumors	harvested	and	processed	for	the	analysis	of	EGFP	posiJve	cells		
as	a	surrogate	marker	for	Tregs	by	ﬂow	cytometry	and	qPCR	studi s.	A)	Data	(ﬂow	cytometry)		
are	the	Mean	±	SE	of	EGFP+	cells	(normalized	to	vehicle	control	mice)	in	CPAF	and		
SC-236	+	CPAF	groups	in	tumors	over	the	period	 f	Jme.		B)	A	repr sent Jve	ﬂ w	a alysis	for		
tumoral	EGFP+	cells	at	day	9	in	CPAF	and	SC-236	+	CPAF	groups	are	shown.		
C)	qPCR	analysis	for	the	EGFP	mRNA	normalized	to	CD3e	in	the	CPAF	a d	SC-236	+	CPAF	groups		
are	shown.		*	Denotes	staJsJcally	signiﬁcant	diﬀerence	(P<0.05)	between	CPAF	versus		
SC-236	+	CPAF	groups.			
	
B 
A 
C D 
Figure 16. Tregs are necessary for etoposide-induced augmentation of tumor 
growth. 
FoxP3EGFP WT mice (n=6-9) were implanted with a single B16F10 tumor on dorsal 
hind flanks. Mice were the  treated with with COX-  i hibitor SC-236 (200 ng) or 
vehicle PB  (100µl) i.p. starting n day of implantati n and every third day. On days 
0, 6 and 12 mice were also treated with CPAF or vehicle. On days 6, 9, 12, 15 and 18, 
tumors were harvested and a alyzed for EGFP+ cells by flow cytometry and qRT-PCR 
as a marker for Tregs. A. Mean percent increase in tumor EGFP+ populations, 
normalized to ve icle treated groups, between CPAF and SC-236 + CPAF tr a ed 
groups over various ti e points. Error bars represent SEM. B. Representative dot plot 
for tumor EGFP+ cells 9 days after CPAF or SC-236 + CPAF treatment. C. Relative 
Egfp mRNA levels normalized to Cd3e in tumors from CPAF or SC-236 + CPAF 
treated mice. D. B16F10 tumors were i planted on bilateral dorsal hind flanks in WT 
mice. Two days prior to tumor implantation, groups of mice (n=7-8) were treated with 
isotype (IgG1 and IgM1  or anti-CD25 (cl nes PC61.5.3 IgG1 an  7D4 IgM1, 1 mg 
each). Tumors were injected with etoposid  and contralateral tumors were measured as 
outlined in Fig. 11. Statistically significant changes are denoted: ** (p < 0.01); * (p < 
0.05). Flow cytometry and qPCR for this figure were kindly contributed by Dr. Sahu. 
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C. Isolated limb perfusion chemotherapy generates PAF and PAFR agonistic ox-
GPCs in humans 
 In light of evidence suggesting that PAFR agonists are generated as a result of 
chemotherapy in mice, it became relevant to study this phenomenon in humans. To test 
the hypothesis that high-dose chemotherapy in ILP generates PAF-like ox-GPCs, 
perfusate samples from human patients undergoing ILP melphalan chemotherapy for 
solid tumors (melanoma, sarcoma) were obtained in collaboration with surgeons Douglas 
S. Tyler and Paul J. Speicher from Duke University, as well as Christopher E. Touloukian 
at Indiana University. To measure PAFR agonists in the samples, lipids were extracted 
from the perfusate samples. Then the PAFR-Ca2+ biochemical assay was used to measure 
the ability of these lipid isolates to activate the PAFR. A basal concentration of PAFR 
agonists were measured from perfusate samples once the perfusion flow was established 
(Control) and did not change after the limb was heated to 40°C. However, a significant 
increase in PAFR activation was measured from perfusates collected 15-60 minutes after 
melphalan was introduced into the perfusate (Figure 17A). Collaborator Prof. Robert 
Murphy, University of Colorado, found by mass spectrometry analysis that various ox-
GPCs were generated during this process. Of significance, production of PAF, ONPAF 
and AzPAF, were significantly increased in perfusates following melphalan 
administration compared to control perfusates (Figure 17B). These findings demonstrate 
that chemotherapy administered by IPL generates a significant quantity of PAFR agonists 
in the clinical setting. 
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Figure 17. Isolated limb perfusion melphalan therapy generates PAFR agonists in 
humans. 
A. ILP samples were drawn at various time points [once the perfusion circuit was 
established (Control), once the limb was heated to 40 °C (Heat), and 15, 30, 45 and 60 
minutes after the initiation of melphalan chemotherapy] from the perfusate of six 
separate subjects undergoing high-dose chemotherapy. Lipid fractions were isolated 
from these perfusate samples and tested by calcium mobilization for PAFR agonistic 
activity as in Fig. 7. The data are the mean ± SEM percentage of maximum 
intracellular calcium release (normalized to 1 µM CPAF) of duplicate samples. B. 
Perfusates collected at two time points (Control and 30 minutes after chemotherapy) 
from three subjects were analyzed by mass spectrometry as in Fig. 9. The data 
depicted are mean mass (ng) of GPC ± SEM per 8 mL of perfusate from three separate 
subjects. * Denotes statistically significant (p < 0.05) changes from values measured in 
control perfusates. Mass spectrometry analysis was kindly generated by Kathleen 
Harrison and Dr. Robert Murphy.  
serve as the source of oxidized phospholipids from the che-
motherapeutic agent intratumoral injections and are thus the
source of chemotherapy-mediated PAF-R agonist formation in
the experimental murine models used. However, it is not clear
whether the source of PAF-R agonists produced during human
regional chemotherapy is derived from the tumors or from
normal tissue.
The present study demonstrates that high levels of PAF-R
agonist activity are measured during regional chemotherapy.
In contrast with the poor responsiveness of metastatic mela-
noma to standard chemotherapy, regional chemotherapy
appears to be one of the most successful antimelanoma
therapies as measured by percentage of clinical responders
(4–6). Hyperthermic isolated limb perfusion, ﬁrst reported in
1958, allows the regional delivery of chemotherapeutic agents
(commonly melphalan) to patients with intransit metastases
localized to extremities that would not be approachable by
surgical resection. The ability to use 10-fold higher than the
standard chemotherapy doses along with heat provides a very
potent combination to kill tumor cells. Another advantage of
regional chemotherapy is the ability to treat the entire area at
highest risk of reoccurrence by eliminating clinically occult
microscopic tumor disease with minimal risk of systemic
toxicity. We hypothesize that this combination of heat and
high-dose melphalan also allows a rather unique environment
that promotes ROS. Though it is possible that standard doses of
systemic chemotherapy could generate immunosuppressive
Ox-GPC PAF-R agonists that impede therapy effectiveness, this
novel and previously unappreciated pathway would more
likely play an important role in regional chemotherapy.
Tumoral resistance to chemotherapy is an important clin-
ical problem and is an area of active study. In contrast to
cellular resistance to the effects of chemotherapy, the present
studies describe a novel mechanism by which chemothera-
peutic agents can subvert antitumor immunity. Indeed, our
previous studies using UVB irradiation of skin as the source for
PAF-R agonists provide several lines of evidence implicating
antitumor immunity, in particular Tregs in the PAF-mediated
effects on experimental B16F10 tumor growth (30). First, PAF
effects are not seen when tumors are placed in immunode-
ﬁcient murine hosts. Second, use of PAF-R–negative B16F10
cells transduced with functional PAF-Rs implanted in WT
versus Ptafr!/! hosts have conﬁrmed that the PAF-R mediat-
ing the response is on the host, not tumor. Finally, use of
neutralizing antibodies against IL10 or depleting Tregs both
block PAF-mediated augmentation of experimental tumor
growth. It is possible that this previously unappreciated path-
way could provide an explanation for why immunotherapy
strategies tend to bemore effective when given to patients who
have not received prior chemotherapy, which according to our
model could potentially tolerize the immune system to the
tumors (44–46).
Exogenous pro-oxidative stressors ranging from aromatic
hydrocarbons to cigarette smoke to UVB radiation have been
shown to induce systemic immunosuppression via PAF-R
signaling, which is blocked by antioxidants (16–18). Apoptotic
cells generate PAF and also contribute to melanoma tumor
progression via PAF-R activation (47). The production of PAF-
R agonists from these various agents begins a cascade of events
leading to systemic immunosuppression. The cytokines that
appear to be critical for the immunosuppression include IL10
and COX-2–generated eicosanoids (14, 15, 18). Mast cells and
regulatory T cells are also implicated in PAF-R–dependent
systemic immunosuppression (18, 30, 48). The present studies
demonstrating that COX-2 inhibitors block chemotherapy-
mediated augmentation of experimental tumor growth are
not only consistent with previous studies characterizing the
role of this eicosanoid-generating enzyme in PAF-mediated
systemic immunosuppression (14, 15, 18), they also provide the
rationale for future studies testing the ability of COX-2 inhi-
bitors to enhance the effectiveness of regional chemotherapy.
It should be noted that COX-2 inhibition has been shown to
exert not only protective properties on the host, but also direct
antitumor effects in a variety of tumor types (49, 50). In
contrast, antioxidant use along with chemotherapy is associ-
ated with controversy due to possible concerns that these
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Figure 6. PAF-R agonists are generated during regional chemotherapy.
A, lipid extracts were obtained from 8 mL of perfusate drawn at various
times [once the circuit was placed (Control), once the limb was at 40"C
(Heat), or following addition of melphalan] from six separate subjects
during isolated limb chemoperfusion and tested for PAF-R activity as
in Fig. 1. The data are the mean # SE percentage of peak intracellular
calcium response (normalized to 1 mmol/L CPAF and 1/10th of blood
volume) of duplicate samples. B, structural characterization of Ox-GPCs
in human subjects. Control and 30 minutes after chemotherapy
perfusates from three subjects were subjected to mass spectrometry as
outlined in Fig. 2. The data depicted are mean # SE ng of GPC per 8 mL
perfusate from three separate subjects. $, statistically signiﬁcant
(P < 0.05) fold changes from values measured in control perfusates.
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agonist activity are measured during regional chemotherapy.
In contrast with the poor responsiveness of metastatic mela-
noma to standard chemotherapy, regional chemotherapy
appears to be one of the most successful antimelanoma
therapies as measured by percentage of clinical responders
(4–6). Hyperthermic isolated limb perfusion, ﬁrst reported in
1958, allows the regional delivery of chemotherapeutic agents
(commonly melphalan) to patients with intransit metastases
localized to extremities that would not be approachable by
surgical resection. The ability to use 10-fold higher than the
standard chemotherapy doses along with heat provides a very
potent combination to kill tumor cells. Another advantage of
regional chemotherapy is the ability to treat the entire area at
highest risk of reoccurrence by eliminating clinically occult
microscopic tumor disease with minimal risk of systemic
toxicity. We hypothesize that this combination of heat and
high-dose melphalan also allows a rather unique environment
that promotes ROS. Though it is possible that standard doses of
systemic che otherapy could generate immunosuppressive
Ox-GPC PAF-R ag ists t at i ede therapy effectiveness, this
novel and previo l reciated pathway would more
likely play an i p r i regional chemotherapy.
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ical problem and is r f active study. In contrast to
cellular resistance to the effects of chemotherapy, the present
studies describe a novel mechanism by which chemothera-
peutic agents can subvert antitumor immunity. Indeed, our
previous studies using UVB irradiation of skin as the source for
PAF-R agonists provide several lines of evidence implicating
antitumor immunity, in particular Tregs in the PAF-mediated
effects on experimental B16F10 tumor growth (30). First, PAF
effects are not seen when tumors are placed in immunode-
ﬁcient murine hosts. Second, use of PAF-R–negative B16F10
cells transduced with functional PAF-Rs implanted in WT
versus Ptafr!/! hosts have conﬁrmed that the PAF-R mediat-
ing the response is on the host, not tumor. Finally, use of
eutralizing antibodies against IL10 or depleting Tregs both
block PAF-mediated augmentation of experimental tumor
growth. It is possible that this previously unappreciated path-
way could rovide an explanation for why immuno herapy
strategies tend to bemore effective when given to patients who
have not received prior chemotherapy, which according to our
model could potentially tolerize the immune system to the
tumors (44–46).
Exogenous pro-oxidative stressors ranging from aromatic
hydrocarbons to cigarette smoke to UVB radiation have been
shown to induce systemic immunosuppression via PAF-R
signaling, which is blocked by antioxidants (16–18). Apoptotic
cells generate PAF and also contribute to melanoma tumor
progression via PAF-R activation (47). The production of PAF-
R agonists from these various agents begins a cascade of events
leading to systemic immunosuppression. The cytokines that
appear to be critical for the immunosuppression include IL10
nd COX-2–generated eicosanoids (14, 15, 18). Mast cells and
regulat ry T cells are also i plicated in PAF-R–dependent
systemic immunosuppression (18, 30, 8). The presen studies
demonstrating that COX-2 inhibitors block chemotherapy-
mediated augmentation of experimental tumor growth are
not only consistent with previous studies characterizing the
role of this eicosanoid-generating enzyme in PAF-mediated
systemic immunosuppression (14, 15, 18), they also provide the
rationale for future studies testing the ability of COX-2 inhi-
bitors to enhance the effectiveness of regional chemotherapy.
It should be noted that COX-2 inhibition has been shown to
exert not only protective properties on the host, but also direct
antitumor effects in a variety of tumor types (49, 50). In
contrast, antioxidant use along with chemotherapy is associ-
ated with controversy due to possible concerns that these
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Figure 6. PAF-R agonists are generated during regional chemotherapy.
A, lipid extracts were obtained from 8 mL of perfusate drawn at various
times [once the circuit was placed (Control), once the limb was at 40"C
(Heat), or following addition of melphalan] from six separate subjects
during isolated limb chemoperfusion and tested for PAF-R activity as
in Fig. 1. The data are the mean # SE percentage of peak intracellular
calcium response (normalized to 1 mmol/L CPAF a d 1/10th of blood
volume) of duplic te samples. B, structural characterization of Ox-GPCs
in human subjects. Control a d 30 minutes after chemotherapy
perfusates from three subjects were subjected to mass spectrometry as
outlined in Fig. 2. The data depicted are mean # SE ng of GPC per 8 mL
perfusate from three separate subjects. $, statistically signiﬁcant
(P < 0.05) fold changes from valu s measured in control perfusates.
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D. PAFR agonist augmentation of tumor growth requires MCs 
 There are several reports that MCs are required for PAF- and UV-induced 
immunosuppression [68, 73, 74, 127, 140]. These reports led to the hypothesis that MCs 
may also be necessary for PAF-induced augmentation of tumor growth. To test this 
hypothesis, mast cell-deficient (Wsh) mice were transplanted with B16F10 tumors and 
the mice were treated with vehicle, or CPAF, on days 0, 6 and 12. Tumor measurements 
over 14 days demonstrated that there were no significant differences in tumor growth 
between mice treated with vehicle or CPAF (Figure 18). This evidence suggests that MCs 
are involved in the tumor promoting effects of PAF. The mechanism by which MCs are 
involved in this pathway remains poorly understood.  
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Figure 18. Tumor measurements in MC-deficient Wsh mice treated with 
intraperitoneal injections of CPAF vs vehicle.  
Wsh mice (n=5) were implanted with a single B16F10 tumor and were treated at day 0 
and every 6 days with intraperitoneal injections of CPAF (250 ng) or vehicle (PBS). 
Growth of untreated tumor was assessed over time as in Fig. 11. The data depicted are 
the mean ± SEM of tumor volume over time. Statistical significance determined using  
two-way ANOVA and using post-hoc Sidak multiple comparisons method for every 
time point, with alpha=5%. 
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II. Mast cell-derived histamine and prostaglandins mediate IL-33 receptor 
dependent PAF-induced immunosuppression 
A. Validation of MC transplant CHS model 
 To elucidate the role of MCs in PAFR-mediated immunosuppression, a 
dinitrofluorobenzene (DNFB) contact hypersensitivity model (CHS) was used (Figure 
19). This particular model is well established in the literature [141-144]. This allergy 
model is better suited than a tumor model to understand the role of PAF and its effects in 
the inflammatory process, for it has well-defined mechanisms. The first set of 
experiments sought to validate a MC transplant model for the use in CHS experiments. 
This model would allow us to study the role of a specific population of mast cells, the 
dermal mast cell. Bone marrow-derived mast cells (BMMCs) were used for this model, 
due to the fact that MC reconstitution into Wsh mice has been well described in the 
literature [69].  
  
Figure 19. CHS model. 
Mice are treated (Tx) with CPAF (250ng, i.p.) or vehicle (PBS, i.p.), histamine (200 
µg s.c.)  or UVB (7.5kJ/m2) on shaved dorsal skin. Five days later mice are sensitized 
to DNFB by painting 25µL of 0.5% DNFB in acetone:olive oil (4:1) on shaved dorsal 
skin. Nine days later ears are measured, one ear of the mice is treated with 0.5% 
DNFB, whereas the other is treated with vehicle. Ear thickness is measured 24 hours 
later. Change in ear thickness is the difference in ear thickness between right and left 
ears. Change in ear thickness is normalized to WT vehicle-treated mice.  
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9	days	
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 BMMC were obtained by flushing femurs and tibia from 8-12 week old mice and 
plating the cells obtained with IL-3 (10 ng/mL) supplemented media for 4 weeks  (Figure 
20A). Flow cytometry analysis revealed that >90% of the cells in culture were FcεRI+ 
ckit+, suggesting that the cells were mature mast cells (Figure 20B). These BMMC were 
then incubated with Fura-2-AM and subsequently treated with CPAF.  BMMCs 
expressed a functional PAFR, due to the ability of Fura-2 loaded MCs to mobilize Ca2+ 
when treated with CPAF (Figure 20C). MCs (106 cells) were then transplanted into the 
dorsal skin of Wsh mice to reconstitute dermal MCs. 
  
Harvest	 IL-3	
4	wks	
A 
B C 
BMMC	
Figure 20. BMMCs express functional PAFR. 
A. Mouse femur and tibia marrow were flushed with IMDM media. Mononuclear cells 
were isolated by Ficoll and plated in media supplemented with IL-3 (10 ng/mL) for 
4-8 weeks. B. After four weeks, cells are analyzed for ckit and FcεRI expression by 
flow cytometry. Culture method yields >90% ckit+ FcεRI+ cells. C. Representative 
Ca2+ mobilization plot. After four weeks, cultured bone marrow cells were incubated 
with Fura-2 AM and treated with CPAF. Subsequent, calcium mobilization was 
measured by fluorimetry. Figures are representative of three experiments.  
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A CHS assay with WT, PAFR KO, Wsh and Wsh mice transplanted with MCs was 
performed that showed that CPAF and UVB irradiation attenuate the ear swelling 
response to DNFB challenge in WT mice, compared to vehicle treated mice (Figure 21). 
However, as depicted in Figure 21, PAFR KO and Wsh mice are insensitive to the 
immunosuppressive effects of CPAF/UVB. Interestingly, MC reconstitution rescued the 
immunosuppressive phenotype of UVB and CPAF in Wsh mice. These findings 
confirmed that MCs are necessary for UVB/PAFR-mediated inhibition of CHS reactions. 
  
Figure 21. MC reconstitution rescues UVB and CPAF induced systemic 
immunosuppression in Wsh mice. 
Groups of 8-12 WT, PAF-R KO, Wsh, or Wsh mice reconstituted with WT MC were 
treated with UVB (7.5kJ/m2) , CPAF (250 ng) , or vehicle 5 days prior to DNFB 
sensitization. Mice were challenged with DNFB on Day 9 post-challenge and ear 
thickness was measured 24 hours later. * Denotes statistically significant differences 
(p<0.05) in ear thickness measurements normalized to vehicle treated mice. Statistical 
significance determined using two-way ANOVA  and the post-hoc Holm-Sidak 
method, with alpha=5%. Each row was analyzed individually, without assuming a 
consistent SD. Error bars represent SEM.  
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B. MC PAFR is necessary for PAFR-mediated immunosuppression 
 Evidence that MCs were necessary for PAFR-mediated immune suppression, led 
to the hypothesis that the MC PAFR is necessary to for PAF to induce systemic 
immunosuppression. To test this hypothesis, WT, Wsh, or Wsh mice transplanted with 
WT or PAFR KO MCs, were treated with either vehicle or CPAF prior to sensitization to 
DNFB and subsequent ear challenge. While WT MC transplantation rescued the 
immunosuppressive ability of CPAF as measured by CHS, transplantation of PAFR KO 
MCs failed to rescue this phenotype (Figure 22). Additionally, if WT MCs were 
transplanted into Wsh mice lacking PAFR (PAFR KO Wsh), CPAF treatment still 
exerted a significant immunosuppressive effect (Figure 22). To verify that negative 
results in PAFR KO MC transplantation were not due to poor transplantation yield, the 
presence of dermal MCs in these mice were demonstrated by Toluidine Blue staining and 
MC numbers were found to be in relatively normal numbers (Figure 23). Together, this 
experimental evidence indicates that the MC PAFR is both necessary and sufficient to 
mediate systemic immunosuppression by PAF.  
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Figure 22. MC PAFR is necessary and sufficient for PAFR-mediated systemic 
immune suppression.  
Groups of 8-9 WT, Wsh, Wsh mice reconstituted with WT, or PAF-R KO MC; or 
PAFR KO Wsh mice reconstituted with WT MC, were treated with CPAF or vehicle 5 
days prior to DNFB sensitization Mice were challenged with DNFB on Day 9 post-
challenge and ear thickness was measured 24 hours later. * Denotes statistically 
significant differences (p<0.05) in ear thickness measurements normalized to vehicle 
treated mice. Statistical significance determined using two-way ANOVA  and the post-
hoc Holm-Sidak method, with alpha=5%. Each row was analyzed individually, 
without assuming a consistent SD. Error bars represent SEM. Experiments 
representative of two separate experiments with 8-9 mice per group in each 
experiment. 
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Figure 23. MC counts in dorsal skin slides stained with toluidine blue.  
Dorsal skin from mice were formalin fixed before storage in ethanol. Sectioned slides 
were stained for MCs by acidified toluidine blue. MC numbers were quantified by 
counting ten high power fields (HPF, 600X). Data depicted is the mean of 4 mice ± 
SEM. * Denotes statistically significant differences (p<0.05) compared to WT. 
Statistical significance determined using one-way ANOVA  and the post-hoc 
Bonferroni method for multiple corrections, with alpha=5%. Error bars represent 
SEM.  
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C. MC-derived histamine is necessary for PAF to induce systemic 
immunosuppression 
 In 1998, Finlay-Jones and colleagues published a paper demonstrating that MC 
deficient mice were not sensitive to immunosuppression by UVB [68]. Furthermore, they 
showed that subcutaneous injection of histamine could elicit similar decrease in CHS 
response as UVB in WT mice. These data led to the hypothesis that MC-derived 
histamine may be one of the mediators involved in the immunosuppressive effects of 
PAF. To test this hypothesis, WT, PAFR KO, or Wsh mice were treated with vehicle, 
CPAF, or histamine before sensitization to DNFB and subsequent ear challenge to DNFB 
for CHS experiments. Unlike CPAF, which has no effect on ear swelling to DNFB 
challenge in Wsh mice and PAFR KO mice, histamine attenuated ear swelling on WT, 
PAFR KO and Wsh mice (Figure 24).  
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Figure 24. MC deficient mice are insensitive to CPAF- but sensitive to histamine-
induced inhibition of CHS reactions. 
Groups of 8-12 WT, PAF-R KO or Wsh mice were treated with histamine (200 µg sc) , 
CPAF (250ng ip), or vehicle 5 days prior to DNFB sensitization. Mice were 
challenged with DNFB on Day 9 post-challenge and ear thickness was measured 24 
hours later. * Denotes statistically significant differences (p<0.05) in ear thickness 
measurements normalized to vehicle treated mice. Statistical significance determined 
using two-way ANOVA  and the post-hoc Holm-Sidak method, with alpha=5%. Each 
row was analyzed individually, without assuming a consistent SD. Error bars represent 
SEM.  
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Subsequently, this evidence led to the hypothesis that histamine is necessary for the 
immunosuppressive effects of PAF. To test this hypothesis, histidine decarboxylase KO 
(HDC KO) mice, which lack the enzyme responsible for histamine biosynthesis, were 
used. Thus, WT and HDC KO mice were treated with vehicle, CPAF or histamine before 
DNFB sensitization and subsequent CHS challenge. HDC KO mice were found to be 
sensitive to immunosuppression by histamine, but insensitive to CPAF-induced 
immunosuppression (Figure 25). This evidence suggests that histamine might be inducing 
systemic immunosuppression down-stream of PAFR activation.  
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Figure 25. HDC KO mice are insensitive to CPAF- but sensitive to histamine-
induced inhibition of CHS reactions. 
Groups of 10-15 WT, or HDC KO mice were treated with histamine, CPAF, or vehicle 
5 days prior to DNFB sensitization. Mice were challenged with DNFB on Day 9 post-
challenge and ear thickness was measured 24 hours later. * Denotes statistically 
significant differences (p<0.05) in ear thickness measurements normalized to vehicle 
treated mice. Statistical significance determined using two-way ANOVA  and the post-
hoc Holm-Sidak method, with alpha=5%. Each row was analyzed individually, 
without assuming a consistent SD. Error bars represent SEM. Figure is representative 
of three pooled experiments. 
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 MCs are the primary, although not the only, source of histamine.  Circulating 
basophils are also a source of this bioactive amine [145]. As such, to test the hypothesis 
that PAFR activation can induce MCs to release histamine and that MC-derived 
histamine is necessary for the immunosuppressive effects of PAF, BMMCs were first 
treated with CPAF in vitro. Using qRT-PCR, mRNA transcript for Hdc was found to be  
upregulated after incubation with CPAF compared to vehicle treatment (Figure 26A). 
Additionally, western blotting demonstrated that HDC protein production is increased as 
well following CPAF treatment (Figure 26B and C). Lastly, CPAF-treated BMMCs were 
found to have greater concentrations of histamine release, compared to vehicle, as 
measured by ELISA (Figure 26D). These findings indicate that MCs are capable of 
releasing histamine following PAFR activation.  
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Figure 26. MC PAFR activation increases HDC mRNA and protein expression.  
A. BMMCs were incubated with CPAF (100 nM) for different time points. Hdc gene 
expression relative to vehicle (1-fold) was measured by qRT-PCR using the 2−∆∆CT 
method and endogenous Gapdh internal control. Each time point is representative of 
three experiments. B. BMMCs were treated for 24hrs with increasing doses of CPAF 
or ionophore/PMA (I/P). Protein fractions of cell lysates were run on an SDS-PAGE 
gel and proteins were transferred to a nitrocellulose membrane. Membranes were 
blotted for HDC and GAPDH. Figure is representative of three experiments. C. 
Densitometry analysis of HDC western blots depict average fold expression of three 
experiments of HDC relative to vehicle (1-fold) using GAPDH as loading control. D. 
Histamine EIA shows average histamine release from three experiments from BMMCs 
incubated with vehicle, CPAF (100nM) or αFcεRI Ab (3µg/mL, positive control)  for 
one hour. Error bars represent SEM. * Denotes statistically significant differences 
(p<0.05). 
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 Thus far the evidence suggests that histamine signaling and MC PAFR activation 
are necessary for the immunosuppressive effects of PAF. While, MC PAFR activation 
induces the release of histamine, MCs are not the only secretors of histamine. These data 
led to the hypothesis that MC-derived histamine is necessary for PAF-induced 
immunosuppression. To test this hypothesis MCs were derived from HDC KO mouse 
BM. HDC KO or WT BMMCs, were then transplanted into Wsh mice. Subsequently, 
these mice and WT controls were treated with vehicle, CPAF, or histamine, 5 days prior 
to sensitization to DNFB for CHS experiment. The results of these experiments 
demonstrated that CPAF and histamine attenuated ear swelling due to antigen challenge 
in all of the mice (Figure 27A). Surprisingly, these experiments suggest that MC HDC 
seems to be dispensable for the immunosuppressive effects of CPAF. Since it is known 
that many cell types express the PAFR, there are likely redundant mechanisms in this 
pathway. In particular, basophils, which express both PAFRs and produce histamine, 
could serve this redundant role. For this reason, the use of a PAFR KO Wsh mouse, 
which not only lacks MCs, but also lacks PAFR expression, could be useful in isolating 
the role of MC HDC in PAFR-mediated immunosuppression. This mouse is useful in 
transplantation, because transplanting PAFR-expressing MCs isolates PAFR expression 
to only one cell type. Using a similar approach, WT or HDC KO BMMCs were 
transplanted into the dorsal skin of PAFR KO Wsh mice. Transplanted mice and WT 
control mice were treated with vehicle, CPAF or histamine, prior to DNFB sensitization. 
After DNFB challenge, histamine treatment blocked ear-swelling responses in all groups, 
however, CPAF treatment failed to suppress the DNFB responses in PAFR KO Wsh mice 
transplanted with HDC KO MCs (Figure 27B).  
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Figure 27. MC-derived histamine is necessary for PAFR inhibition of CHS 
response. 
WT or HDC KO MCs were transplanted into the dorsal skin of Wsh (A) or PAFR KO/
Wsh (B) mice. Groups of 5-8 mice along with WT were treated with vehicle, CPAF 
i.p. or histamine s.c. 5 days before sensitization to DNFB for CHS assay. CPAF does 
not confer immunosuppression in PAFR KO Wsh mice reconstituted with HDC KO 
MCs.  Error bars represent SEM. * Denotes statistically significant differences 
(p<0.05) in ear thickness measurements normalized to vehicle treated mice. Statistical 
significance determined using two-way ANOVA  and the post-hoc Holm-Sidak 
method, with alpha=5%. Each row was analyzed individually, without assuming a 
consistent SD. Experiments representative of two different experiments with n=5-7 
mice per group in each experiment.  
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 These data suggest that MC-derived histamine plays a role in PAFR-mediated 
immunosuppression. While not necessary, MC-derived histamine may be sufficient to 
induce systemic immunosuppression down-stream of PAFR activation. 
D. MC COX-2 is necessary for PAF-induced immunosuppression 
 Previous work has demonstrated the importance of prostaglandins for UV light to 
suppress the immune system. In particular, Narumiya and colleagues recently showed 
that the prostaglandin receptor EP4 mediates UV-induced systemic immunosuppression 
[131]. Our group has previously shown using a CHS assay that immunosuppression 
induced by UVB, cigarette smoke and CPAF can all be blocked by COX-2 inhibitors [24, 
25, 135]. In a similar fashion, WT mice were also treated with COX-2 inhibitor SC-236 
and vehicle, CPAF or histamine, 5 days prior to sensitization to DNFB. After DNFB 
challenge, ear measurements demonstrated that COX-2 inhibitors can block the 
immunosuppressive effects of CPAF and histamine (Figure 28).  
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Figure 28. COX-2 inhibitor SC-236 blocks CPAF- and histamine-induced 
inhibition of CHS responses. 
Groups of 6-8 mice along with WT were treated with vehicle or SC-236 (200 ng), and 
vehicle, CPAF i.p. or histamine s.c. 5 days before sensitization to DNFB for CHS 
assay. Error bars represent SEM. * Denotes statistically significant differences 
(p<0.05) in ear thickness measurements normalized to vehicle treated mice. Statistical 
significance determined using one-way ANOVA  and the post-hoc Dunnett’s method, 
with alpha=5%. Each row was analyzed individually, without assuming a consistent 
SD. Experiments representative of two different experiments with n=4-5 mice per 
group in the second experiment.  
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These data suggest that COX-2 is involved in mediating the suppressive response of PAF, 
but possibly down-stream of histamine. To test the hypothesis that MC PAFR activation 
could induce prostaglandin release, BMMCs were first treated with CPAF. qPCR and 
western blotting, revealed that COX-2 mRNA and protein levels are upregulated in 
BMMCs treated with CPAF (Figure 29A,B and C). Additionally, as shown in Figure 
29D, treating BMMCs with CPAF resulted in PGE2 release in BMMCs. These findings 
demonstrate that MC PAFR activation induces COX-2 expression as well as 
prostaglandin release.   
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Figure 29. MC PAFR activation results in COX-2 mRNA and protein expression, 
and PGE2 production. 
A. BMMCs were incubated with CPAF (100 nM) for different time points. Ptgs2 gene 
expression relative to vehicle (1-fold) was measured by qRT-PCR using the 2−∆∆CT 
method and endogenous Gapdh internal control. Figure is representative of three 
separate experiments. B. BMMCs were treated for 24hrs with increasing doses of 
CPAF or ionophore/PMA (I/P). Protein fractions of cell lysates were run on an SDS-
PAGE gel and proteins were transferred to a nitrocellulose membrane. Membranes 
were blotted for COX-2 and GAPDH. Figure is representative of three separate 
experiments. C. Densitometry analysis of COX-2 western blots depict average fold 
expression of three experiments of HDC relative to vehicle (1-fold) using GAPDH as 
loading control. D. PGE2 EIA shows PGE2 release from BMMCs incubated with 
vehicle, ionophore/PMA (I/P), or increasing concentrations of CPAF at eight hours. 
Figure is representative of three separate experiments. Error bars represent SEM. * 
Denotes statistically significant differences (p<0.05). 
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 Given the findings that PAFR activation can induce COX-2 expression in MCs, 
thus led to hypothesis that MC COX-2 plays a role in the immunosuppressive mechanism 
of PAF. In collaboration with Drs. Garret Fitzgerald and Sven-Christian Pawelzik at the 
University of Pennsylvania, MCs were derived from the BM of Mcpt5-cre/Ptgs2flox/flox 
mice for transplantation into Wsh mice and subsequent CHS experiments [146-148]. 
Attempts at generating germline COX-2 KO mice on a C57BL/6 background resulted in 
unhealthy mice that fail to thrive and have reproductive complications [149]. To take a 
parallel approach, Fitzgerald and Pawelzik have generated COX-2 floxed mice that have 
a MC-specific driven cre recombinase. MCPT5, mast cell protease 5, is a mast cell 
specific protease that is expressed in dermal MCs, which are connective tissue type MCs. 
Thus, BMMCs were cultured from the BM of these mice. BMMCs from Mcpt5-
cre/Ptgs2flox/flox mice transplanted into Wsh mice will mature and differentiate normally, 
as has been demonstrated in the literature [69, 147, 148, 150], into dermal mast cells that 
express MCPT5. Thus, MCPT5 expression will result in the excision of exons VI - VIII 
from COX-2 resulting in selective loss of COX-2 activity expression. Using this 
approach BMMCs derived from Mcpt5-cre/Ptgs2flox/flox (COX-2 KO) or Ptgs2flox/flox 
(COX-2 WT) mice were transplanted into Wsh mice. These mice and WT controls were 
treated with vehicle, CPAF, or histamine, 5 days prior to sensitization to DNFB. After 
DNFB challenge, ear measurements showed that histamine and CPAF reduced ear 
swelling in both WT mice and Wsh mice transplanted with COX-WT MCs. In contrast, 
Wsh mice transplanted with COX-2 KO MCs were resistant to immunosuppression by 
CPAF (Figure 30). These findings suggest that MC COX-2 contributes the suppressive 
effects of PAF on the immune system.   
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Figure 30. MC COX-2 is necessary for CPAF- but not histamine-induced 
inhibition of CHS responses. 
WT (Ptgs2flox/flox) or COX-2 KO (Mcpt5-cre/Ptgs2flox/flox	) MCs were transplanted into 
the dorsal skin of Wsh mice. Groups of 7-10 mice along with WT were treated with 
vehicle, CPAF i.p. or histamine s.c. 5 days before sensitization to DNFB for CHS 
assay. CPAF does not confer immunosuppression in Wsh mice reconstituted with 
COX-2 KO MCs.  Error bars represent SEM. * Denotes statistically significant 
differences (p<0.05) in ear thickness measurements normalized to vehicle treated 
mice. Statistical significance determined using two-way ANOVA  and the post-hoc 
Holm-Sidak method, with alpha=5%. Each row was analyzed individually, without 
assuming a consistent SD. Experiments representative of two different experiments 
each containing groups of n=5-10 mice per group in each experiment.  
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E. The role of TGFβ  in PAFR-mediated systemic immunosuppression 
 Tregs are one of the main cell mediators of tolerance and anti-inflammatory 
processes and they mediate their effects through various mechanisms including the 
release of IL-10 and TGFβ [151-153]. While natural Tregs persist following thymic 
selection, inducible Tregs (iTregs) differentiate from naïve T cells in the presence of 
TGFβ in their microenvironment [151]. These iTregs play a critical role in attenuating the 
inflammatory tide. Our group recently published data suggesting that Tregs might be 
involved in mediating the immunosuppressive effects of PAF [24, 25]. These findings led 
to the hypothesis that TGFβ may also be involved in the immunosuppressive effects of 
PAF by virtue of its role in Treg differentiation. To test this hypothesis, WT mice were 
injected with the TGFβR1 inhibitor LY364947 or vehicle at the time of treatment with 
vehicle, CPAF or histamine, 5 days prior to sensitization to DNFB. After DNFB ear 
challenge, ear measurements demonstrated that treating mice with LY364947 blocked the 
suppressive effects of CPAF and histamine on CHS reactions to DNFB (Figure 31).  
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Figure 31. TGFβR1 inhibitor LY364947 blocks for CPAF- and histamine-induced 
inhibition of CHS responses. 
Groups of 5 WT mice were treated with vehicle or TGFβ-R1 inhibitor LY364947 1mg/
kg q.o.d. i.p., and CPAF i.p.,  Histamine s.c., or vehicle 5 days prior to DNFB 
sensitization. Ears were measured 24hrs after DNFB challenge on Day 9. Error bars 
represent SEM. * Denotes statistically significant differences (p<0.05) in ear thickness 
measurements normalized to vehicle treated mice. Statistical significance determined 
using two-way ANOVA  and the post-hoc Holm-Sidak method, with alpha=5%. Each 
row was analyzed individually, without assuming a consistent SD. Figure is 
representative of two different experiments each with n=5 per group. 
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These data led to the hypothesis that MC PAFR stimulation might induce TGFβ release. 
To test this hypothesis, BMMCs were treated with CPAF and qPCR analysis 
demonstrated that Tgfb1 mRNA transcript is upregulated after 4 hours (Figure 32A). 
However, flow cytometry analysis of intracellular staining or ELISA did not provide 
evidence of increased TGFβ protein expression or increased levels of released TGFβ1 
protein (Figure 32B and C). These studies suggest that while TGFβ may be required for 
PAF to promote the suppression of immune responses, MC PAFR activation does not 
appear to induce MCs to release TGFβ. It is noteworthy, however, that MCs do readily 
secrete significant amounts of TGFβ and while release is not induced by PAF, MC 
migration to lymph nodes could effectively deliver TGFβ to a site of T cell differentiation 
in a PAFR-independent manner.  This scenario where TGFβ exerts its effects down-
stream of MC PAFR activation could explain how a TGFβR inhibitor could block CPAF- 
and histamine-mediated inhibition of CHS reactions. Thus, the MC PAFR could be 
important in trafficking the MC to the lymph nodes but not for producing the necessary 
TGFβ.  
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Figure 32. CPAF treatment of BMMC results in increased TGFβ1 mRNA but not 
protein levels. 
A. BMMCs were incubated with CPAF (100 nM) for different time points. Tgfb1 gene 
expression relative to vehicle (1-fold) was measured by qRT-PCR using the 2−∆∆CT 
method and endogenous Gapdh internal control. Figure is representative of three 
separate experiments. B. BMMCs were treated for 24hrs with increasing doses of 
CPAF or ionophore/PMA (I/P). Cells were permeabilized with saponin and stained for 
TGFβ-bound LAP. Figure is representative of three experiments. Mean fluorescence 
intensities are depicted in the table below. C. TGFβ ELISA shows TGFβ1 release from 
BMMCs incubated with vehicle, ionophore/PMA (I/P), or CPAF for 24 hours. Figure 
is representative of three experiments. Error bars represent SEM. * Denotes 
statistically significant differences (p<0.05). 
 
B A 
C 
102 103 104
TGFb/LAP - PE
0
50
100
150
200
250
Co
un
t
SampleID Mean : Comp-PE-A
PMA/Ionophore 3563 
1uM CPAF 1322 
100nM CPAF 1347 
10nM CPAF 1304 
1nM CPAF 1361 
Vehicle 1439 
Isotype 781 
No Inhibitor
4 8 12 24
0
2
4
6
8
Tgfb1
Incubation time (hours)
Fo
ld
 e
xp
re
ss
io
n 
ov
er
 v
eh
ic
le * *
*
*
  92 
F. PAF induces MC migration to draining LNs 
 Recent work in the field has demonstrated that once MCs are activated by UVB or 
PAF, MCs subsequently migrate to draining LNs. In particular Ullrich and colleagues 
have shown that this MC migration may be blocked by AMD3100, a CXCR4 inhibitor, 
resulting in reduced sensitivity to immunosuppression by CPAF and UVB. Additionally, 
this group has reported that PGE2 and UVB treatment upregulates CXCL12, the ligand 
for CXCR4, in inguinal LNs [73, 74]. Together, these data suggest that MCs migrate to 
draining LNs following PAFR activation. Still, it has been shown in the literature that 
CXCR4 is regulated by prostaglandins including PGE2, although there is some debate as 
to whether prostaglandins promote or inhibit migration [38, 154-158]. These findings led 
to the hypothesis that PAF-induced MC prostaglandin release might be the down-stream 
effectors of the MC PAFR by regulating MC CXCR4 expression. To show that 
prostaglandins mediate PAFR-activated MC migration to LNs, Wsh mice reconstituted 
with dermal CD45.1 WT BMMCs were either treated with vehicle or CPAF, and vehicle 
or COX-2 inhibitor SC-236. Bilateral inguinal LNs were harvested 24 hours later. One 
LN was formalin fixed, sectioned and stained for MCs with toluidine blue. The other LN 
was passed through a 70µm filter to render a single cell suspension that was stained and 
subjected to flow cytometry analysis. Histology revealed the presence of significant 
numbers of MCs in LNs from mice treated with CPAF (Figure 33). Interestingly, these 
mast cell populations were absent in mice treated with both CPAF and SC-236, 
suggesting that COX-2 inhibitors could block the PAFR-mediated migration of MCs to 
LNs. Flow cytometry analysis revealed similar findings (Figure 34).  
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Figure 33. Histological analysis of PAF-induced MC migration to LNs blocked by 
COX-2 inhibitors. 
A. CD45.1 BOYJ BMMCs (106) were transplanted into the dorsal skin of Wsh mice. 
Groups of 2-3 mice were then treated with vehicle or CPAF, and vehicle or SC-236. 
Inguinal LNs were harvested 24hrs later, formalin fixed, sectioned and stained by 
toluidine blue. Arrows point at MCs. Images were taken at 400X. Black bar represents 
50µm. B. MC numbers were quantified using by counting all the MCs per slide and 
dividing by the number of LNs on the slide. Data depicted is the mean ± SEM of three 
slides from 1-2 mice per group. Error bars represent SEM. * Denotes statistically 
significant differences (p<0.05). 
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Figure 34. Flow cytometry analysis of PAF-induced MC migration to LNs 
blocked by COX-2 inhibitors. 
A. CD45.1 BOYJ BMMCs (106) were transplanted into the dorsal skin of Wsh mice. 
Groups of 3 mice were then treated with vehicle or CPAF, and vehicle or SC-236. 
Inguinal LNs were harvested 24hrs later and passed through a 70µm filter to make a 
single cell suspension. Cells were stained and analyzed by flow cytometry. Figure 
depicts representative dot plots of cells that are Live ckit+ CD45.1+ CD4-. B. Total 
number of MCs per LN were calculated. Mean MC numbers of 4 separate experiments 
are shown. Error bars represent SEM. * Denotes statistically significant differences 
(p<0.05). 
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Subsequent experiments demonstrated that CPAF treated MCs upregulate CXCR4 
transcript after 12 hours (Figure 35A). Flow cytometry analysis also demonstrated that 
CXCR4 is upregulated in the surface of MCs treated with CPAF as compared to vehicle 
treated cells. Interestingly, however, incubation of these cells with COX-2 inhibitor SC-
236 could block this increase in surface CXCR4 expression (Figure 35B). Additionally, 
incubation of MCs with EP4 agonist CAY10598 resulted in increases surface expression 
of CXCR4 in MCs (Figure 35C). These data suggest that MC CXCR4 expression may be 
regulated by prostaglandins acting in an autocrine or paracrine fashion by activating the 
MC EP4 receptor. In other words, it seems that the machinery needed for PAFR activated 
MCs to migrate to LNs is regulated by prostaglandins.  
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Figure 35. CPAF upregulation of CXCR4 is blocked by COX-2 inhibitor SC-236, 
while activation of EP4 is sufficient to increase MC surface CXCR4 expression. 
A. BMMCs were incubated with increasing concentrations of CPAF for 12hrs. Cxcr4 
gene expression relative to vehicle (1-fold) was measured by qRT-PCR using the 
2−∆∆CT method and endogenous Gapdh internal control. Figure is representative of 
three experiments. B. BMMCs were treated for 24hrs with vehicle, CPAF (B), EP4 
agonist CAY10598 (C) or ionophore/PMA (I/P), and vehicle or SC-236 (500 nM). 
Cells were stained for surface CXCR4 expression with a conjugated antibody. Figures 
are representative of three experiments. Error bars represent SEM. * Denotes 
statistically significant differences (p<0.05). 
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 Ongoing experiments are aimed at investigating the functional role of PAF-
induced MC histamine release in MC migration to LNs. It has been previously found that 
histamine can directly upregulate COX-2 expression in cells [159] and that UV-induced 
production of prostaglandins in the skin can be mediated by histamine [160]. 
Additionally, it has been found that secretory granules released from MCs can travel 
down lymphatic vessels to affect distant LN microenvironments [81], and that PGE2 can 
upregulate CXCL12, the chemokine ligand necessary for CXCR4-mediated migration, in 
inguinal LNs [73]. These findings led to the hypothesis that histamine released from MCs 
could upregulate to COX-2 in LNs to provide the prostaglandins necessary for CXCL12 
release and thus provide a chemokine gradient for CXCR4-mediated MC migration to 
draining LNs. To test this hypothesis, preliminary experiments consisted of injecting 
histamine subcutaneously, or PBS in the dorsal skin of WT mice. After one hour, 
draining LNs were harvested and homogenized. Western blotting from the LN lysates 
revealed increased COX-2 protein expression in draining LNs (Figure 36). These data 
support the hypothesis that histamine may play a role in setting up the chemokine 
gradient for MC migration to draining LNs. Yet, further work is needed to fully delineate 
the mechanism of PAF-induced MC migration to draining LNs in the context of 
subsequent systemic immunosuppression.  
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Figure 36. Subcutaneous histamine increases COX-2 expression in skin DLNs. 
A. Histamine (200 µg in 100µL s.c.) or PBS (100µL) was injected into the dorsal skin 
of WT mice. Inguinal LNs were harvested one hour later. Whole LNs were 
homogenized by mechanical syringe methods while on ice. Lysates were separated by 
polyacrylamide gel electrophoresis, transferred onto a nitrocellulose membrane, and 
blotted for COX-2 and GAPDH by western blotting techniques. B. Densitometry 
analysis of COX-2 western blots depict average fold expression of three experiments 
of HDC relative to vehicle (1-fold) using GAPDH as loading control. Error bars 
represent SEM. * Denotes statistically significant differences (p<0.05). 
B A 
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G. IL-33 signaling plays a role in PAF-induced systemic immunosuppression 
 Recently, UVB irradiation, as well as systemic CPAF treatment, has been shown 
to increase the expression of alarmin IL-33 in the skin [161]. Additionally, treatment with 
high dose IL-33 has been shown to reduce the Th1 response in cell mediated 
hypersensitivity [161]. This evidence led to the hypothesis that IL-33 may be necessary 
for PAF to suppress the immune system following UVB irradiation. To test this 
hypothesis, mice lacking the IL-33 receptor, ST2 KO mice, were tested for the sensitivity 
to immunosuppression by UVB or CPAF. Thus, ST2 KO mice were treated with vehicle, 
UVB, CPAF, or histamine, five days prior to sensitization with DNFB. A CHS assay 
revealed that UVB and histamine showed a robust decrease in ear swelling following 
challenge to DNFB (Figure 37). CPAF, however, demonstrated some decrease in ear 
swelling, but still lesser in magnitude than UVB irradiation (Figure 37). To follow up on 
this experiment, WT and ST2 KO mice were treated with vehicle, CPAF, or histamine 
prior to elicitation of CHS responses. ST2 KO mice were found to be less sensitive to the 
suppressive effects of CPAF on CHS responses (Figure 38). Similar results were found 
using IL-33 KO mice. 
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Figure 37. ST2 KO mice are sensitive to UVB- and histamine-induced but have 
decreased sensitivity to CPAF-induced inhibition of CHS reactions. 
Groups of 5-10 ST2 KO mice were treated with vehicle, UVB, CPAF, or histamine 5 
days prior to DNFB sensitization. Mice were challenged with DNFB on Day 9 post-
challenge and ear thickness was measured 24 hours later. * Denotes statistically 
significant differences (p<0.05) in ear thickness measurements normalized to vehicle 
treated mice. Statistical significance determined using one-way ANOVA  and the post-
hoc Sidak method, with alpha=5%. Each row was analyzed individually, without 
assuming a consistent SD. Error bars represent SEM. Figure is representative of one 
experiment. 
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Figure 38. CPAF does not suppress CHS response in ST2 KO mice. 
Groups of 5 WT or ST2 KO mice were treated with vehicle, CPAF, or histamine 5 
days prior to DNFB sensitization. Mice were challenged with DNFB on Day 9 post-
challenge and ear thickness was measured 24 hours later. * Denotes statistically 
significant differences (p<0.05) in ear thickness measurements normalized to vehicle 
treated mice. Statistical significance determined using two-way ANOVA  and the post-
hoc Holm-Sidak method, with alpha=5%. Each row was analyzed individually, 
without assuming a consistent SD. Error bars represent SEM. Figure is representative 
of three experiments with n=5 mice per group per experiment. 
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 There has been a large body of work demonstrating that MCs mediate 
inflammatory mechanisms following stimulation by IL-33. Particularly in arthritis 
models, MCs have been shown to be involved in a perpetual IL-33/TNFα cycle [162, 
163]. These findings led the hypothesis that IL-33 signaling may be involved in the 
mechanism by which MCs mediate the immunosuppressive effects of PAF. To test this 
hypothesis, first WT BMMCs were tested for expression the IL-33 receptor by flow 
cytometry, and were found to express ST2 (Figure 39A). CPAF and PGE2 were also 
found to upregulate ST2 expression in MCs by qPCR (Figure 39B and C). Then, BMMCs 
from WT, IL-33 KO or ST2 KO mice were transplanted into the dorsal skin of Wsh mice. 
These mice as well as WT controls were treated with vehicle, CPAF, or histamine, 5 days 
prior to sensitization to DNFB and subsequent ear challenge to DNFB. Wsh mice 
transplanted with WT and IL-33 KO MCs were found to be sensitive to the 
immunosuppressive effects of CPAF on ear challenge responses (Figure 40). In mice 
transplanted with ST2 KO MCs, however, CPAF did not demonstrate significant 
reduction in response to DNFB. Similar results were observed in PAFR KO Wsh mice 
transplanted with WT or ST2 KO MCs (Figure 41). This evidence suggests that while IL-
33 may play a role in mediating PAF-induced immunosuppression, MC activation by IL-
33, but not its release by MCs, may be involved.  
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Figure 39. MCs express ST2 which is upregulated by CPAF and PGE2.   
A. BMMCs were unstained (red) or stained with APC-conjugated ST2 antibody (grey) 
and analyzed by flow cytometry. Figure is representative of three experiments. B and 
C. BMMCs were incubated with increasing concentrations of CPAF (12 hrs, B), PGE2 
(4 hrs, C) or IP. Il1rl1 gene expression relative to vehicle (1-fold) was measured by 
qRT-PCR using the 2−∆∆CT method and endogenous Gapdh internal control. Figure is 
representative of one experiment.  
A 
B C 
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Figure 40. MC ST2, but not MC IL-33, is necessary for PAFR-mediated systemic 
immunosuppression. 
WT, ST2 KO, or IL-33 KO MCs were transplanted into the dorsal skin of Wsh mice. 
Groups of 4-6 transplanted mice along with WT and Wsh were treated with vehicle, 
CPAF i.p. or histamine s.c. 5 days before sensitization to DNFB for CHS assay. CPAF 
does not confer immunosuppression in Wsh mice reconstituted with ST2 KO MCs.  
Error bars represent SEM. * Denotes statistically significant differences (p<0.05) in 
ear thickness measurements normalized to vehicle treated mice. Statistical significance 
determined using two-way ANOVA  and the post-hoc Holm-Sidak method, with 
alpha=5%. Each row was analyzed individually, without assuming a consistent SD. 
Figure representative of one experiment.  
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Figure 41. CPAF does not suppress CHS responses in PAFR KO Wsh mice 
reconstituted with ST2 KO MCs. 
WT, or ST2 KO MCs were transplanted into the dorsal skin of PAFR KO Wsh mice. 
Groups of 6-12 transplanted mice along with WT were treated with vehicle, CPAF i.p. 
or histamine s.c. 5 days before sensitization to DNFB for CHS assay. CPAF does not 
confer immunosuppression in Wsh mice reconstituted with ST2 KO MCs.  Error bars 
represent SEM. * Denotes statistically significant differences (p<0.05) in ear thickness 
measurements normalized to vehicle treated mice. Statistical significance determined 
using two-way ANOVA  and the post-hoc Holm-Sidak method, with alpha=5%. Each 
row was analyzed individually, without assuming a consistent SD. Figure 
representative of one experiment.  
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 As discussed previously, activation of MCs by IL-33 has been shown to mediate 
strong pro-inflammatory responses [162, 163]. This evidence along with previous CHS 
experiments, led to the hypothesis that MC ST2 activation might also initiate anti-
inflammatory mechanisms, such as the induction of TGFβ. To test this hypothesis, MCs 
were incubated with IL-33 and flow cytometry analysis revealed that TGFβ expression is 
strongly upregulated by IL-33 as assessed by intracellular staining (Figure 42). Since, 
MC ST2 activation was found to induce anti-inflammatory mechanisms, exploring the 
mechanisms of how this pathway is involved in the suppressive mechanism of PAF 
proved to be important. Initial experiments found that ST2 is upregulated in MCs 
following PAFR activation (Figure 39B). These data helped to develop the hypothesis 
PAF and IL-33 may have some pharmacological interaction to induce the expression of 
anti-inflammatory mediators. Preliminary experiments show that PAF can potentiate IL-
33 induced IL-10 expression, and synergize with IL-33 to induce COX-2 expression 
(Figure 43). However, PAF did not seem to have an effect on IL-33-induced IL-33 
expression. 
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Figure 42. IL-33 upregulates TGFβ in MCs. 
BMMCs were treated for 24hrs with increasing doses of IL-33. Cells were 
permeabilized with saponin and stained for TGFβ-bound LAP. Mean fluorescence are 
depicted in the table below. Figure is representative of three experiments 
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Figure 43. CPAF and IL-33 synergize to upregulate IL-10 and COX-2. 
BMMCs were incubated with CPAF (100 nM) and IL-33 (10ng/mL) for 24hrs (Ptgs2) 
or 4hrs (Il33 and Il10). Gene expression relative to vehicle (1-fold) was measured by 
qRT-PCR using the 2−∆∆CT method and endogenous Gapdh internal control. Figure is 
representative of one experiment. Error bars represent SEM. * Denotes statistically 
significant differences (p<0.05) compared to CPAF and IL-33 treatment groups.  
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Chapter 4: Discussion and Future Directions 
I. Chemotherapy induces systemic immunosuppression via the generation of 
PAFR agonists 
 The cytotoxic effects of chemotherapeutics pose a significant concern to patients. 
Despite narrow therapeutic concentrations, significant side effects pose a dosage limit to 
resistant tumors. Suppression of the immune system is a potential side effect of 
chemotherapy, which can promote opportunistic infections and diminish the effect of 
both host anti-tumor effects as well as exogenous immunotherapies [164-167]. While the 
mechanism of this suppression is controversial, some reports show that chemotherapy 
could induce a “rebound phase” via the activation of a chemotherapy induced “cytokine 
storm” [165, 168]. This might in part be the result of the bivalent pro-inflammatory and 
anti-inflammatory nature of PAFR signaling. I hypothesize that the effects of 
chemotherapy on the host immune system could be the result of PAFR agonists generated 
during chemotherapy that therefore mediate systemic immunosuppression. The approach 
to study this hypothesis is two fold: 1.) Test to see if chemotherapy treated melanoma 
generates PAFR agonists, and 2.) Test to see if chemotherapy induced PAFR agonists can 
promote tumor growth of a second tumor.  
 Using our specific calcium mobilization fluorometric assay involving PAFR-
positive KBP cells, I found that chemotherapeutics, namely etoposide, cisplatin and 
melphalan, could generate PAFR agonists from mouse and human melanoma cells in 
vitro (Figures 7). These experiments revealed that incubating melanoma cells with 
chemotherapy generates the greatest concentration of PAFR agonists after two hours of 
incubation. Interestingly, this trend seemed to decrease after four hours of incubation, 
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possibly suggesting that the PAFR agonists being generated were being metabolized, or 
possibly that some of the ox-GPCs are inhibiting PAFR activation. In fact some of the 
ox-GPCs generated are partial agonists of the PAFR, which in high concentrations could 
decrease the response of full agonists.  
 Using a similar approach to measure PAFR agonists by calcium mobilization, 
PAFR-expressing melanoma cells (B16P) generated greater concentrations of PAFR 
agonists when treated with chemotherapeutics, dacarbazine, etoposide and cisplatin, as 
compared to PAFR-null melanoma (B16M) cells (Figure 8A). Additionally, pretreating 
melanoma cells with antioxidants NAC and vitamin C attenuated the generation of PAFR 
agonists by chemotherapy treatment (Figure 8B). In light of these data, this 
chemotherapy-induced generation of PAFR seems to be partially driven by both 
enzymatic, as well as, non-enzymatic PAF synthesis mechanisms. As antioxidants can 
attenuate the generation of these PAFR agonists (Figure 8B), this suggests that this 
process involves the oxidation of GPCs by ROS. Even with antioxidants, however, a 
significant amount of PAFR agonists were still detected, suggesting the presence of 
another mechanism that generates PAFR agonists. This could be the result of PAFR 
activation on melanoma cells (Figure 8A) or the activation of PLA2/LPCAT via another 
mechanism following treatment with chemotherapeutics. More studies are necessary to 
describe this mechanism fully, but may involve the activation of apoptotic or necrotic 
pathways. Structural studies by Prof. Robert Murphy using mass spectrometry confirmed 
that chemotherapeutic agents generated both PAF as well as ox-GPC PAFR agonists 
(Figure 9). Still, the exact mechanism by which these PAFR agonists are generated 
requires further investigation.  
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 Our group previously demonstrated that systemic PAFR activation by UVB or 
CPAF promotes tumor growth [25]. These observations led to the hypothesis that PAFR 
agonists generated as a result of chemotherapy could also promote tumor growth. The 
calcium mobilization functional assay, described above, demonstrated that lipid extracts 
from implanted tumors in mice treated with chemotherapy contained higher 
concentrations of PAFR agonists than those treated with vehicle (Figure 10). This 
generation of PAFR agonists in vivo was found to be blocked by feeding the mice an 
antioxidant diet consisting of vitamin C chow and NAC in water (Figure 10A). These 
data led to the hypothesis that chemotherapy induced generation of PAFR agonists in 
vivo could modulate the growth of a second tumor. To test this hypothesis, a dual tumor 
model was used, where one tumor was treated with intratumoral chemotherapy and the 
contralateral tumor was measured. Tumor measurements demonstrated that PAFR 
agonists generated by chemotherapy could promote growth of a contralateral tumor in 
WT tumor-burdened mice and not in PAFR-KO hosts (Figure 11 and 12). Feeding the 
mice an antioxidant diet, however, blocked the tumor growth promoting effect of 
chemotherapy (Figures 11C, 11D and 12B), suggesting that this promotion of tumor 
growth is in part due to the generation of ox-GPC PAFR agonists. Tumor measurements 
did not demonstrate significant tumor growth differences in tumors treated with 
intratumoral injections within a treatment group, yet some differences were observed 
between treatment groups. Namely, tumor growth differences in injected tumors between 
vehicle and chemotherapy-treated groups were found (Figure 13). In fact, decreased 
growth in contralateral (untreated) tumors that were measured was noted when 
comparing mice treated with chemotherapy versus vehicle (Figure 11B). This is likely the 
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result of chemotherapy acting appropriately both locally and systemically to attenuate 
tumor growth. The chemotherapeutics injected are likely not confined to the tumor 
volume, but rather diffusing systemically. Additionally, WT hosts promoted greater 
growth of a second tumor following intratumoral chemotherapy than PAFR KO hosts 
(Figure 11B), indicating that this increase in tumor growth is due to the effects of PAF.  
 Previous work in the field has demonstrated that the immunosuppressive effects 
of PAF are mediated by COX-2 derived prostaglandins and Tregs [24, 25, 36], and that 
the immunosuppressive effects of UVB are mediated by MCs [68, 73]. These lines of 
evidence led to the hypothesis that these chemotherapeutic agents may also be involved 
in mediating the suppressive effects of chemotherapy on the immune system. Using a 
single tumor model, COX-2 inhibitors blocked the increase in tumor growth driven by 
CPAF (Figures 14A and B). Notably, neither CPAF nor COX-2 inhibitors exerted any 
effects on tumor growth in PAFR KO mice (Figure 14C). Using a dual tumor model, the 
chemotherapy-induced promotion of tumor growth by melphalan and etoposide was also 
found to be blocked by COX-2 inhibitor SC-236 (Figure 15).  
 Interestingly, CPAF was found to increase intratumoral and draining LN Treg 
numbers in a process attenuated by COX-2 inhibitors (Figure 16ABC). These data led to 
the hypothesis that chemotherapy-induced promotion of tumor growth may be mediated 
by Tregs. To test this hypothesis a dual tumor model was used, where mice were treated 
with a Treg-depleting antibody cocktail prior to tumor implantation. Left tumors were 
treated with chemotherapy in these mice and the subsequent tumor growth measurements 
demonstrated that the tumor growth promoting effects of chemotherapy could be blocked 
by Treg depleting antibodies (Figure 16D). This evidence suggests that Tregs are 
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necessary to mediate chemotherapy-induced immunosuppression. Lastly, I sought to test 
the hypothesis that MCs are involved in the tumor growth-promoting effects of PAF. 
Using a single tumor model, MC-deficient Wsh mice were not found to be sensitive to 
the tumor growth promoting effects of CPAF (Figure 18), suggesting that MCs may be 
involved in PAFR-mediated increase in tumor growth.  
 The work presented here demonstrates that therapeutic doses of chemotherapeutic 
agents can induce the generation of PAFR agonists when treating cancer cells. In fact 
even humans, PAFR agonists were also found in perfusate samples from patients 
undergoing ILP melphalan chemotherapy (Figure 17). In collaboration with Prof. Robert 
Murphy, PAF and several PAFR agonistic ox-GPCs were found in the lipid extracts from 
these perfusates (Figure 17B). Chemotherapy appears to promote the oxidation of GPCs 
via the generation of ROS, and that these chemotherapy-induced PAF species promote 
growth of a second tumor by mediating systemic immunosuppression that is mediated by 
COX-2, Tregs, and MCs. These findings are consistent with recent published data that 
chemotherapy induces suppression of the immune system [164-167], and that PAF-
induced systemic immunosuppression is mediated by prostaglandins and COX-2 [24, 25, 
36].  
 As discussed previously, the immunosuppressive effects of chemotherapeutics is 
not a novel observation. In fact since its synthesis in 1953 by Bergel and Stock, 
melphalan, an alkalating analog, has displayed these characteristics during its use in 
treating leukemia and solid tumors [169]. Due to its structure as a phenylalanine-
substituted mustard gas, melphalan is particularly effective against active tumors that use 
large amounts of phenylalanine such as melanoma. [169]. Originally, however, since 
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1988 melphalan has been used in autologous bone-marrow transplantation [169]. This use 
is largely due to well-described immunosuppression and bone-marrow ablation 
characteristics of high-dose melphalan, especially when administered intravenously 
[170]. The data in this manuscript support the hypothesis that chemotherapeutics such as 
etoposide, melphalan, dacarbazine, and cisplatin, induce systemic immunosuppression 
via the generation of PAFR-agonistic ox-GPCs in a process blocked by antioxidants, 
COX-2 inhibitors, and Treg-depleting antibodies (Figure 44). Still, more work is 
necessary to shed light on the mechanism of immune suppression by chemotherapy, 
where the data in this manuscript provides some light to the role of PAF in this 
mechanism. Part of this is the impetus for Part II, where the role of MCs in the 
mechanism of PAFR-mediated systemic immunosuppression is further investigated.  
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Figure 44. Current model for chemotherapy-induced PAFR-dependent increase 
in tumor growth. 
Chemotherapy induces the generation of PAFR-agonistic ox-GPCs via the oxidation of 
GPCs by ROS. The generation of these PAFR agonists is blocked by antioxidants. 
Subsequent PAFR activation induces Treg-dependent increase in tumor growth via 
systemic immunosuppression. This increase in tumor growth can be blocked by 
COX-2 inhibitors and Treg-depleting antibodies.  
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II. Mast cell-derived histamine and prostaglandins mediate IL-33 receptor 
dependent PAF-induced immunosuppression 
 PAF and the activation of the PAFR have been implicated in mediating the 
suppressive effects of pro-oxidative stressors on the immune response. These oxidative 
stressors include UVB, jet fuel, cigarette smoke, photodynamic therapy, and now 
chemotherapy [24, 25, 36, 140, 171]. Still, the mechanism of this suppression remains to 
be fully elucidated. While key players have been identified, namely COX-2, IL-10, Tregs 
and MCs among others to be uncovered, their interactions have not been thoroughly 
investigated. These findings shaped the hypothesis that dermal MCs may play a central 
role in initiating the suppressive effects of PAF on immune responses. To test this 
hypothesis, MC transplantation and CHS models were used to investigate the suppressive 
effects of PAFR stimulated dermal MCs on cell-mediated immunity. Initial experiments 
demonstrated that MCs derived from BM expressed a functional PAFR as measured by 
calcium mobilization (Figure 20). Additionally, reconstitution of dermal MCs in Wsh 
mice rescued the sensitivity to immunosuppression by UVB and CPAF absent in MC-
deficient mice (Figure 21). These findings led to the hypothesis that the MC PAFR is 
necessary to mediate the immunosuppressive effects of PAF. To test this hypothesis, 
BMMCs from WT or PAFR KO mice were transplanted into Wsh mice. This experiment 
demonstrated that MC PAFR was necessary for CPAF to the attenuate ear swelling 
challenge response (Figure 22). Additionally, by reconstituting PAFR KO Wsh mice with 
WT MCs, MC PAFR activation was shown to be sufficient to suppress the CHS response 
(Figure 22). Notably, a similar number of MCs were found in reconstituted Wsh mice 
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compared to WT mice (Figure 23). Together, this evidence suggests that the MC PAFR is 
both necessary and sufficient to mediate PAF systemic immunosuppression.  
 It was previously shown that subcutaneous histamine injections could attenuate 
CHS responses in WT and MC-deficient mice [68]. In line with these observations, 
histamine was found to also suppress CHS responses in PAFR KO mice (Figure 24). 
Additionally, HDC KO mice appear to be sensitive to immunosuppression by histamine, 
but not CPAF (Figure 25). Together, these data suggest that histamine may promote 
systemic immunosuppression downstream of PAFR activation. MCs are one of the main 
contributors of histamine in inflammation. In fact, MCs are known to release large stores 
of histamine by rapid degranulation following FcεRI coupling, in a process involving 
intracellular calcium mobilization [172].  This thought process led to the hypothesis that 
MCs might release histamine following PAFR activation and that MC-derived histamine 
is an important mediator of PAF-induced immunosuppression.  MC PAFR activation 
revealed upregulation of HDC mRNA and protein expression, and stimulation of 
histamine release (Figure 26). Surprisingly, transplantation of HDC KO MCs into Wsh 
mice still rescued the immunosuppressive effects of CPAF, but not if HDC KO MCs 
were transplanted into Wsh mice lacking PAFR (Figure 27). This evidence suggests that 
MC histamine release plays a role in PAFR-mediated systemic immunosuppression, but 
that there are other compensatory pathways due to the expression of PAFR on other cells 
(e.g. basophils, keratinocytes, fibroblasts, endothelial cells). Still, it seems that MC PAFR 
is necessary, but perhaps activation of other PAFR expressing cells contribute to reaching 
the threshold necessary to suppress immune responses. For example, it has been 
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previously shown that PAFR activation on keratinocytes upregulates COX-2 expression 
[130] and treatment with CPAF upregulates IL-33 expression in fibroblasts [161].  
 As previously mentioned, COX-2 has been shown to be involved in mediating the 
immunosuppressive effects of UVB and PAF. Furthermore, PAFR activation has been 
shown to upregulate COX-2 [130]. In line with this evidence, PAFR activation also 
upregulates COX-2 in MCs (Figure 29) and MC COX-2 expression appears to be 
necessary for PAFR-mediated systemic immunosuppression as found by CHS (Figure 
30). Additionally, COX-2 inhibitors were shown to block CPAF and histamine 
immunosuppression in WT mice (Figure 28), suggesting that COX-2 is involved 
downstream of PAF and histamine receptor activation. One of the proposed mechanisms 
for the involvement of COX-2 in this pathway is the interaction of prostaglandins and the 
regulation of cell chemotaxis. In particular, PGE2 has been shown to mediate 
immunosuppressive responses by promoting chemotaxis of anti-inflammatory cells, 
while attenuating the attraction of pro-inflammatory cells [158]. One such example of 
this is the ability of PGE2 to induce CXCL12 expression in endothelial cells [73]. 
Additionally, the Ullrich laboratory has shown that MC PAFR activation upregulates 
CXCR4 expression in MCs and promotes a necessary chemotaxis to draining LNs to 
mediate immunosuppression [73]. These findings led to the hypothesis that MC CXCR4 
might be under the control of prostaglandins released by PAFR activation. To test this 
hypothesis, Wsh mice transplanted dorsally with CD45.1 WT BMMCs were treated with 
CPAF or vehicle, and SC-236 or vehicle. Histological (Figure 33) and flow cytometry 
(Figure 34) analysis of inguinal LNs in these mice revealed that CPAF induced the 
migration of MCs to LNs in a process blocked by COX-2 inhibitors. Furthermore, COX-
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2 inhibitors were found to block the upregulation of CXCR4 by PAFR activation in MCs 
(Figure 35B), and PGE2 receptor, EP4, activation was found to independently upregulate 
MC surface CXCR4 expression (Figure 35C). Lastly, it remains to be fully elucidated 
how the CXCL12 chemokine gradient is established to facilitate PAF-induced MC 
migration to draining LNs. In light of evidence that MC mediators can travel down 
lymphatic vessels to affect the LN microenvironment [81], PGE2 can upregulate CXCL12 
LNs [73], and that histamine can promote prostaglandin release [159, 160], led to the 
hypothesis that histamine released following MC PAFR activation could subsequently 
promote a CXCL12 chemokine gradient by upregulating COX-2 in draining LNs. 
Preliminary data suggested that subcutaneous histamine injection can increase COX-2 
levels in inguinal LNs (Figure 36). These data support the hypothesis that histamine 
released following MC PAFR activation could promote COX-2 expression to provide the 
source of prostaglandins necessary to mount a CXCL12 chemokine gradient. Together 
this evidence suggests that the role of prostaglandins, and possibly both MC-derived 
prostaglandins and histamine, are important to mediate PAF-induced systemic 
immunosuppression and it may do so in part by regulating MC CXCR4 and LN COX-2 
expression.  
 MC CXCR4 has been shown to be important for UVB-induced systemic 
immunosuppression, because MC migration to LNs via this chemokine pathway has been 
shown to be necessary [73, 74]. MC migration to LNs is not a new finding as MCs have 
been shown to migrate to LNs after various inflammatory stimuli [72]. While the role of 
MCs in the LN is a current topic of further investigation, it seems that MCs can be a 
pivotal player in directly influencing lymphocyte activation. Once in the LN, MCs could 
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release prostaglandins, histamine, and TGFβ, amongst other mediators, to influence 
lymphocyte activation [173], or recruit other immunosuppressive cell types [91, 93, 96, 
174]. While CPAF and histamine-induced systemic immunosuppression could be blocked 
by TGFβ inhibitors (Figure 31), MC PAFR activation failed to induce TGFβ release 
(Figure 32). Still, basal TGFβ or histamine release could become relevant once MCs 
enter draining LNs. The immunosuppressive effect of MCs in the local microenvironment 
has been observed before [88]. However, MCs can upregulate TGFβ expression in 
response to IL-33, which seems to be involved in PAFR-mediated systemic 
immunosuppression. 
 The alarmin IL-33 has been shown to be released as a result of cell damage and to 
initiate immune responses. Recently, it was shown to be upregulated in skin irradiated 
with UVB and upregulated in dermal fibroblast after CPAF treatment [161]. These data 
led to the hypothesis that IL-33 may be important for PAFR-mediated systemic 
immunosuppression. Initial experiments demonstrated that mice lacking the IL-33 
receptor (ST2), were sensitive to systemic immunosuppression by UVB and histamine, 
but had a decreased response to CPAF (Figure 37). Further experiments showed that 
compared to WT mice, ST2 KO mice had a decreased, but not significant, response to 
CPAF (Figure 38), and that WT BMMCs express ST2 that can be upregulated by 
treatment with CPAF and PGE2 (Figure 39). Next, MC ST2, but not MC IL-33 was found 
to be necessary to mediate PAF-induced immunosuppression (Figure 40 and 41). 
Moreover, BMMCs treated with IL-33 were found to upregulate TGFβ expression 
(Figure 42), and IL-33 appears to synergize with CPAF to upregulate IL-10 and COX-2 
expression (Figure 43). This evidence suggests that ST2 might be important in the 
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promotion of immunosuppression by CPAF, but that UVB activates other pathways that 
do not involve IL-33 signaling. For example, cis-UCA could be mediating the 
immunosuppressive effects of UVB in a process that does not require IL-33 signaling. In 
the context of PAF, however, IL-33 might be mediating systemic immunosuppression 
through the upregulation of IL-10, TGFβ, and COX-2, which have been implicated in 
UV-induced systemic immunosuppression. Still, the exact source of IL-33 relevant to this 
mechanism is a topic of current investigation. In line with previous observations, 
however, it appears that ST2 KO mice are still sensitive to immunosuppression by 
histamine, suggesting that histamine might mediate suppression of the immune system 
downstream of ST2 and PAFR.  
 These results suggest that COX-2, IL-33, and histamine mediate the 
immunosuppressive effects of PAF (Figure 45). It appears that a pro-inflammatory 
threshold must be reached before subsequent immunosuppression ensues, where COX-2-
derived prostaglandins and histamine contribute to the pro-inflammatory “cytokine 
storm” activation energy. Of particular interest, would be to identify the site of action of 
histamine, PGE2, and IL-33. The current evidence in this work gives rise to two 
hypotheses for how MCs may be mediating immune suppression: 1.) Either by direct 
interactions with lymphocytes in draining LNs following CXCR4-dependent MC 
migration to LNs, or 2.) By MC release of mediators in the skin that act locally or travel 
via lymphatics to affect T cell activation in draining LNs. As mentioned before, MC 
migration to draining LNs has been shown to be necessary to mediate systemic 
immunosuppression, and that this migration is mediated via CXCR4 chemotaxis 
following MC PAFR activation [73, 74, 127]. It has also been shown that MC-derived 
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particles can travel via lymphatic vessels to signal to distant LNs [81]. This could be 
important because histamine and prostaglandins released following MC PAFR activation 
could travel to draining LNs to influence T cell activity. Additionally, one of the main 
APCs in the skin, dendritic cell migration has been shown to be repressed by PGD2 but 
promoted by PGE2 [154, 155, 157, 175-178]. The migration of DCs could potentially 
play a role, because the downregulation of DC activity or migration in the skin could also 
account for decreased CHS responses by virtue of decreasing presentation of antigen 
during sensitization. Thus, the possibility exists that these two mechanisms contribute to 
the immune suppressive response of PAF, MC migration-dependent and –independent 
mechanisms.  
 Additionally, the kinetics of MC histamine and PGE2 release may be relevant to 
study further. MC PAFR activation seems to induce early histamine release within an 
hour and PGE2 release within 8 hours of activation, which may be relevant in the skin or 
in LNs provided that these mediators can flow to draining LNs. Conversely, mRNA and 
protein expression of HDC and COX-2 are upregulated after 12-24 hours. The expression 
timeline of this increase in protein expression more closely correlates with the timeline of 
MC migration to LNs following MC PAFR activation. These observations suggest that 
MC histamine and prostaglandin release could become relevant in the LN following MC 
migration. Thus, histamine and PGE2 seem to have both early and late effects. 
Furthermore, it remains to be further elucidated where in the mechanism IL-33 is 
relevant.  
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Figure 45. Current model of the role of MCs in PAFR-mediated systemic 
immunosuppression.  
MC PAFR activation stimulates PGE2 and histamine release that reactivate MCs via 
possible paracrine mechanisms to upregulate MC CXCR4. Additionally, histamine and 
PGE2 can flow to draining lymph nodes to upregulate lymph node CXCL12 
expression to provide the chemokine gradient for CXCR4-mediated MC migration to 
draining lymph nodes over the course of 24 hours. In the LNs, MCs induce Treg-
mediated systemic immunosuppression, possibly by promoting Treg differentiation via 
the release of TGFβ subsequent to IL-33 stimulation. This immunosuppression is 
mediated by Tregs, partly by the decrease in Th1 populations, and resulting decreased 
CHS reactions. 
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III. Future Directions 
 To further dissect the role of MC migration in the suppressive effects of PAF on 
the immune system, I plan to investigate the role of MC COX-2 and histamine in PAFR-
induced MC migration. Preliminary studies have demonstrated that COX-2 inhibitors can 
block the migration of MCs to draining LNs. Suggesting the importance of COX-2 
derived prostaglandins in this mechanism. I also have some data suggesting that 
histamine and PGE2 can have autocrine effects in MCs, suggesting that that MC COX-2 
and histamine may be important for PAF-induced migration of MCs to draining LNs. To 
study this, I plan on studying underlying autocrine effects of PGE2 and histamine in vitro, 
as well as the ability of COX-2 and HDC KO MC to migrate to draining LNs following 
PAFR activation. Additionally, I plan to investigate the role of prostaglandins released 
after MC PAFR activation on DC migration and subsequent changes in T cell activation. 
Lastly, moving forward with the hypothesis that MCs migrate to draining LNs, I want to 
test the role of MC PAFR activation on T cell differentiation. Previously, unstimulated 
MCs have been shown to promote Treg differentiation when cultured in vitro [179]. Still, 
the effects of histamine on Tregs is controversial, where some evidence suggests that 
histamine represses [92, 180] and promotes [145, 181] Treg function. Thus, I want to test 
the hypothesis that PAFR-activated MCs can promote the differentiation of Tregs in LNs 
by co-culture.  
 The mechanistic role of MCs in the immunosuppression of chemotherapy is not 
well elucidated. While dermal MCs could be conceivably activated by PAF-species made 
by chemotherapy, which MCs and how the MCs are activated in the context of tumor 
immunity are still a topic of investigation. Aside from the role of MCs, it remains to be 
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elucidated whether the suppression of the immune system by PAF is antigen specific. To 
investigate this further, I propose to make use of OVA-expressing melanoma cells and 
OT-I mice, whose majority of the T cell receptor repertoire is specific for the recognition 
of the OVA antigen. For these experiments, antitumor immunity can be modeled by 
transplanting OT-I T cells into mice burdened with OVA-expressing tumors. The tumor 
modulating effects of chemo and CPAF can then be studied in the context of antitumor 
immunity. Using this tumor model, the immunosuppressive effects of PAF on the 
adaptive immune response, versus non-specific anti-tumor immunity (such as NK cell 
and macrophages) can be investigated.  
 While pharmacokinetics and pharmacodynamics of melphalan treatment in 
humans have been carried out [169, 170], further studies are needed to uncover where 
PAF may be relevant in the immunosuppressive effects of chemotherapy, particularly 
etoposide and melphalan. For instance, it remains to be elucidated whether the PAFR 
agonists generated by chemotherapy are only formed by intratumoral chemotherapy or if 
systemic chemotherapy will also produce similar results. Perhaps, the generation and 
action of these PAFR agonists is confined to the tumor microenvironment. Moreover, it 
remains to be known if COX-2 inhibitors may be effective at reducing 
immunosuppressive effects of chemotherapy in humans. Further clinical studies aimed at 
investigating the efficacy of chemotherapy in patients taking COX-2 inhibitors would be 
necessary.  
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